https://curecurrent.com/trials/bravo-study-laquinimod-double-blind-placebo-controlled-study-in-participants-with-relapsing-remitting-multiple-sclerosis-106006https://curecurrent.com/trials/ms-mosaic-a-longitudinal-research-study-on-multiple-sclerosis-106007https://curecurrent.com/trials/a-multi-site-trial-of-ms-inform-fatigue-management-resource-106008https://curecurrent.com/trials/effectiveness-of-hippotherapy-simulator-in-pwms-106009https://curecurrent.com/trials/mbct-and-cbt-for-chronic-pain-in-multiple-sclerosis-106010https://curecurrent.com/trials/evaluation-of-the-prevalence-of-oculomotor-disorders-in-patients-with-radiologically-isolated-syndrome-106011https://curecurrent.com/trials/l-test-in-multiple-sclerosis-106012https://curecurrent.com/trials/therapeutic-effects-of-line-dancing-in-people-with-ms-106013https://curecurrent.com/trials/self-administered-hyperinsufflation-chest-on-the-risk-of-low-respiratory-infection-in-patients-with-multiple-sclerosis-w-106014https://curecurrent.com/trials/vr-treadmill-combined-intervention-for-enhancing-mobility-and-cognitive-function-in-patients-with-multiple-sclerosis-106015https://curecurrent.com/trials/mesenchymal-cells-from-autologous-bone-marrow-administered-intravenously-in-patients-diagnosed-with-multiple-sclerosis-106016https://curecurrent.com/trials/follow-up-study-of-the-effectiveness-of-virtual-reality-therapy-in-ms-patients-106017https://curecurrent.com/trials/muscle-strain-in-multiple-sclerosis-patients-measured-by-ultrasound-speckle-tracking-technique-106018https://curecurrent.com/trials/non-interventional-study-to-assess-adherence-to-treatment-for-patients-with-rms-main-ms-106019https://curecurrent.com/trials/offering-support-and-electronic-resources-for-care-partners-of-those-with-multiple-sclerosis-106020https://curecurrent.com/trials/effects-of-telerehabilitation-based-pelvic-floor-muscle-training-in-people-with-multiple-sclerosis-106021https://curecurrent.com/trials/structural-and-functional-impairment-of-multiple-organs-in-patients-with-systemic-sclerosis-a-mr-imaging-study-106022https://curecurrent.com/trials/collection-of-blood-samples-from-patients-with-relapsing-ms-who-developed-itp-after-receiving-lemtrada-106023https://curecurrent.com/trials/phase-iiib-iv-long-term-follow-up-study-for-patients-who-participated-in-camms03409-106024https://curecurrent.com/trials/a-pilot-study-of-warm-and-cold-compress-to-reduce-injection-site-erythema-due-to-peginterferon-beta-1a-in-ms-106025https://curecurrent.com/trials/analysis-of-ms-patients-who-have-had-greater-than-60-infusions-of-natalizumab-106026https://curecurrent.com/trials/safety-and-efficacy-of-cladribine-therapy-after-anti-cd20-therapy-106027https://curecurrent.com/trials/the-effect-of-emotional-freedom-technique-on-depression-anxiety-and-distress-of-individuals-with-multiple-sclerosis-106028https://curecurrent.com/trials/a-study-to-analyze-the-effect-of-acupuncture-on-mobility-and-quality-of-life-in-multiple-sclerosis-106029https://curecurrent.com/trials/automated-edss-score-calculation-by-smartphone-application-106030https://curecurrent.com/trials/famciclovir-in-multiple-sclerosis-106031https://curecurrent.com/trials/ocrelizumab-or-alemtuzumab-compared-with-autologous-hematopoietic-stem-cell-transplantation-in-multiple-sclerosis-a-phas-106032https://curecurrent.com/trials/applying-speed-of-processing-training-to-individuals-with-multiple-sclerosis-106033https://curecurrent.com/trials/investigating-the-home-based-rcts-of-pilates-exercises-and-cognitive-rehabilitation-exercises-for-executive-functions-an-106034https://curecurrent.com/trials/ocrelizumab-effects-on-physiological-and-cognitive-changes-in-multiple-sclerosis-106035https://curecurrent.com/trials/neuromodulation-in-ms-using-translingual-stimulation-106036https://curecurrent.com/trials/a-phase-2-clinical-study-in-subjects-with-primary-progressive-multiple-sclerosis-to-assess-the-efficacy-safety-and-toler-106037https://curecurrent.com/trials/real-world-effectiveness-of-natalizumab-extended-interval-dosing-in-a-french-cohort-106038https://curecurrent.com/trials/a-pilot-trial-of-remotely-supervised-transcranial-direct-current-stimulation-rs-tdcs-to-enhance-motor-learning-in-progre-106039https://curecurrent.com/trials/comparison-of-brain-atrophy-rates-cognition-and-patient-reported-outcomes-in-ms-patients-using-long-term-fingolimod-and-106040https://curecurrent.com/trials/kinematic-assessment-in-multiple-sclerosis-106041https://curecurrent.com/trials/mobile-attentional-bias-modification-training-in-pediatric-ms-106042https://curecurrent.com/trials/investigation-of-novel-immunological-biomarkers-by-mass-cytometry-in-patients-with-early-multiple-sclerosis-cisco-106043https://curecurrent.com/trials/phase-1b-multiple-ascending-dose-study-of-foralumab-in-primary-and-secondary-progressive-ms-106044https://curecurrent.com/trials/neurofilaments-for-neda-assessing-in-ms-106045https://curecurrent.com/trials/optic-neuritis-differential-diagnosis-study-106046https://curecurrent.com/trials/time-to-be-ready-to-void-a-new-tool-to-assess-the-time-needed-to-perform-micturition-in-multiple-sclerosis-106047https://curecurrent.com/trials/is-the-severity-of-urinary-disorders-related-to-falls-in-people-with-multiple-sclerosis-106048https://curecurrent.com/trials/out-of-pocket-cost-communication-in-multiple-sclerosis-patients-106049https://curecurrent.com/trials/early-detection-and-paramedical-care-of-sexual-difficulties-in-nervous-system-diseases-example-of-multiple-sclerosis-and-106050https://curecurrent.com/trials/effects-of-ozanimod-on-immune-mediated-mechanisms-of-neurodegeneration-in-multiple-sclerosis-a-preclinical-study-106051https://curecurrent.com/trials/5-ht7-receptor-implication-in-inflammatory-mechanisms-in-multiple-sclerosis-106052https://curecurrent.com/trials/development-of-automated-analysis-to-electroencephelogram-eeg-data-in-patients-treated-at-the-sagol-hyperbaric-medicine-106053https://curecurrent.com/trials/sequential-natalizumab-alemtuzumab-therapy-in-patients-with-relapsing-forms-of-multiple-sclerosis-106054https://curecurrent.com/trials/g-eo-gait-rehabilitation-training-in-progressive-multiple-sclerosis-106055https://curecurrent.com/trials/virtual-reality-vr-to-improve-quality-of-life-in-patients-diagnosed-with-neurological-disorders-106056https://curecurrent.com/trials/examining-the-neural-effects-of-a-behavioral-intervention-for-physical-activity-in-multiple-sclerosis-106057https://curecurrent.com/trials/multiple-sclerosis-in-the-elderly-epidemiology-clinical-and-mri-characteristics-106058https://curecurrent.com/trials/evaluation-of-relapse-presence-in-multiple-sclerosis-106059https://curecurrent.com/trials/open-label-placebos-to-treat-fatigue-in-multiple-sclerosis-106060https://curecurrent.com/trials/promoting-aerobic-training-in-multiple-sclerosis-106061https://curecurrent.com/trials/a-study-of-ocrelizumab-in-participants-with-relapsing-remitting-multiple-sclerosis-rrms-who-have-had-a-suboptimal-respon-106062https://curecurrent.com/trials/development-and-evaluation-of-the-self-management-module-in-patients-with-multiple-sclerosis-106063https://curecurrent.com/trials/eye-movements-recording-using-a-smartphone-comparison-to-standard-video-oculography-in-patients-with-multiple-sclerosis-106064https://curecurrent.com/trials/safety-of-therapeutic-step-down-in-neuromyelitis-optica-106065https://curecurrent.com/trials/telems-feasibility-of-remote-patient-visits-in-ms-106066https://curecurrent.com/trials/lifestyle-weight-management-program-interviews-and-stakeholder-meetings-106067https://curecurrent.com/trials/a-safety-and-efficacy-study-of-ads-5102-in-patients-with-multiple-sclerosis-and-walking-impairment-106068https://curecurrent.com/trials/measuring-active-microglia-in-progressive-multiple-sclerosis-106069https://curecurrent.com/trials/efficacy-of-cognitive-behavioral-therapy-on-fatigue-cognition-and-inflammatory-biomarkers-in-ms-patients-106070https://curecurrent.com/trials/safety-study-in-patients-with-multiple-sclerosis-treated-fingolimod-or-other-approved-disease-modifying-therapies-106071https://curecurrent.com/trials/a-study-to-assess-the-safety-tolerability-and-pharmacokinetics-of-biib078-in-adults-with-c9orf72-associated-amyotrophic-106072https://curecurrent.com/trials/a-prospective-biomarker-study-in-active-spms-subjects-treated-with-cladribine-tablets-106073https://curecurrent.com/trials/nature-of-the-link-between-executive-functions-and-theory-of-mind-in-multiple-sclerosis-106074https://curecurrent.com/trials/investigation-of-the-effects-of-selective-exercise-training-in-multiple-sclerosis-106075https://curecurrent.com/trials/improving-learning-in-hispanics-with-tbi-or-ms-106076https://curecurrent.com/trials/neurology-inpatient-clinical-education-trial-106077https://curecurrent.com/trials/a-study-to-provide-complementary-efficacy-safety-and-patient-reported-outcomes-data-in-participants-with-active-relapsin-106078https://curecurrent.com/trials/examining-the-effects-of-a-telehealth-self-management-intervention-in-multiple-sclerosis-106079https://curecurrent.com/trials/bioequivalence-study-of-bafiertam-190-mg-and-vumerity-462-mg-delayed-release-capsules-in-fasting-healthy-subjects-106080https://curecurrent.com/trials/promoting-physical-activity-behavior-in-persons-with-multiple-sclerosis-106081https://curecurrent.com/trials/adherence-to-mediterranean-diet-and-cardiovascular-health-in-multiple-sclerosis-female-patients-a-case-control-study-106082https://curecurrent.com/trials/safety-and-efficacy-of-ads-5102-in-multiple-sclerosis-patients-with-walking-impairment-106083https://curecurrent.com/trials/impact-of-fingolimod-adherence-on-outcomes-106084https://curecurrent.com/trials/tdcs-for-the-management-of-multiple-sclerosis-related-fatigue-106085https://curecurrent.com/trials/search-for-diagnostic-and-prognostic-biomarkers-in-systemic-sclerosis-and-inflammatory-myopathies-106086https://curecurrent.com/trials/a-study-to-evaluate-the-long-term-safety-tolerability-and-effect-on-disease-course-106087https://curecurrent.com/trials/study-to-assess-medication-satisfaction-in-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-copaxone-106088https://curecurrent.com/trials/a-study-in-subjects-with-relapsing-remitting-multiple-sclerosis-rrms-to-assess-the-efficacy-safety-and-tolerability-of-g-106089https://curecurrent.com/trials/a-study-to-evaluate-the-long-term-safety-tolerability-and-effect-of-daily-oral-laquinimod-0-6-mg-on-disease-course-in-su-106090https://curecurrent.com/trials/study-to-assess-the-efficacy-and-safety-of-ublituximab-in-participants-with-relapsing-forms-of-multiple-sclerosis-rms-106091https://curecurrent.com/trials/study-to-assess-the-efficacy-and-safety-of-ublituximab-in-participants-with-relapsing-forms-of-multiple-sclerosis-rms-ul-106092https://curecurrent.com/trials/multiple-sclerosis-t-cell-b-cell-exploration-106093https://curecurrent.com/trials/individualized-physiotherapy-and-activity-coaching-for-multiple-sclerosis-106094https://curecurrent.com/trials/study-of-myms-in-participants-with-a-diagnosis-of-multiple-sclerosis-106095https://curecurrent.com/trials/safety-and-efficacy-of-avp-923-in-the-treatment-of-central-neuropathic-pain-in-multiple-sclerosis-106096https://curecurrent.com/trials/efficacy-and-safety-of-ofatumumab-compared-to-teriflunomide-in-patients-with-relapsing-multiple-sclerosis-106097https://curecurrent.com/trials/barriers-to-physical-activity-in-people-with-ms-106098https://curecurrent.com/trials/observational-study-in-patients-with-relapsing-remitting-multiple-sclerosis-switched-to-bafiertam-from-dimethyl-fumarate-106099https://curecurrent.com/trials/respiratory-functions-in-pediatric-onset-multiple-sclerosis-106100https://curecurrent.com/trials/phase-iv-study-betaseron-versus-copaxone-for-relapsing-remitting-or-cis-forms-of-ms-using-triple-dose-gad-3-t-mri-106101https://curecurrent.com/trials/efficacy-of-clean-intermittent-catheterization-cic-in-multiple-sclerosis-ms-patients-with-bladder-dysfunction-106102https://curecurrent.com/trials/the-efficacy-safety-and-tolerability-of-laquinimod-in-participants-with-relapsing-remitting-multiple-sclerosis-rrms-106103https://curecurrent.com/trials/a-study-to-evaluate-2-doses-of-oral-administration-of-laquinimod-compared-to-interferon-ss-1a-administered-by-injection-106104https://curecurrent.com/trials/diagnosic-and-pronostic-values-of-kappa-and-lambda-free-light-chains-in-central-nervous-system-inflammatory-diseases-106105https://curecurrent.com/trials/a-safety-and-biomarker-study-of-alzt-op1a-in-subjects-with-mild-moderate-als-disease-106106https://curecurrent.com/trials/phase-i-study-evaluating-safety-and-tolerability-of-escalating-single-and-multiple-doses-of-of-pipe-307-and-food-effect-106107https://curecurrent.com/trials/safety-and-efficacy-of-orally-administered-laquinimod-versus-placebo-for-treatment-of-relapsing-remitting-multiple-scler-106108https://curecurrent.com/trials/alemtuzumab-in-autoimmune-inflammatory-neurodegeneration-mechanisms-of-action-and-neuroprotective-potential-106109https://curecurrent.com/trials/feasibility-study-of-tolerogenic-fibroblasts-in-patients-with-refractory-multiple-sclerosis-106110https://curecurrent.com/trials/safety-and-efficacy-of-intrathecal-rituximab-in-patients-with-multiple-sclerosis-106111https://curecurrent.com/trials/central-and-peripheral-nervous-system-changes-as-markers-of-disease-progression-in-multiple-sclerosis-106112https://curecurrent.com/trials/multicenter-observational-study-for-the-evaluation-in-clinical-practice-of-urinary-disorders-in-multiple-sclerosis-106113https://curecurrent.com/trials/hamster-a-novel-smartphone-communication-tool-for-people-with-ms-106114https://curecurrent.com/trials/rituximab-versus-fumarate-in-newly-diagnosed-multiple-sclerosis-106115https://curecurrent.com/trials/immune-response-to-covid-19-vaccine-in-multiple-sclerosis-patients-treated-with-teriflunomide-and-alemtuzumab-106116https://curecurrent.com/trials/exercise-and-learning-and-memory-in-multiple-sclerosis-106117https://curecurrent.com/trials/a-12-week-randomized-open-label-parallel-group-multicenter-study-to-evaluate-bioequivalence-of-20-mg-subcutaneous-ofatum-106118https://curecurrent.com/trials/a-study-of-immune-phenotype-biomarkers-in-patients-with-relapsing-multiple-sclerosis-rms-after-treatment-with-0-5mg-fing-106119https://curecurrent.com/trials/gaze-and-postural-stability-in-multiple-sclerosis-106120https://curecurrent.com/trials/feasibility-and-acceptability-of-orthotic-shorts-for-people-with-multiple-sclerosis-106121https://curecurrent.com/trials/efficacy-and-safety-of-ofatumumab-compared-to-teriflunomide-in-patients-with-relapsing-multiple-sclerosis-106122https://curecurrent.com/trials/home-based-exergames-to-improve-cognitive-function-in-multiple-sclerosis-106123https://curecurrent.com/trials/functional-intermuscular-reduction-of-spasticity-106124https://curecurrent.com/trials/cerebral-blood-flow-and-tdcs-106125https://curecurrent.com/trials/the-wearing-off-phenomenon-of-ocrelizumab-in-patients-with-multiple-sclerosis-106126https://curecurrent.com/trials/my-ms-toolkit-coaching-a-guided-web-based-symptom-self-management-program-for-people-with-ms-106127https://curecurrent.com/trials/functions-physical-activity-and-employment-for-individuals-with-ms-a-pilot-feasibility-study-106128https://curecurrent.com/trials/effects-of-teriflunomide-aubagio-on-cognitive-and-vocational-outcomes-in-multiple-sclerosis-106129https://curecurrent.com/trials/ultrasound-guided-percutaneous-neuromodulation-in-spasticity-106130https://curecurrent.com/trials/study-to-assess-effect-and-safety-of-high-dose-of-biotin-qizenday-in-progressive-multiple-sclerosis-106131https://curecurrent.com/trials/validate-factor-viii-trending-for-ms-relapse-106132https://curecurrent.com/trials/efficacy-and-safety-of-bcd-063-and-copaxone-teva-in-patients-with-relapsing-remitting-multiple-sclerosis-106133https://curecurrent.com/trials/3d-phase-sensitive-inversion-recuperation-mri-to-detect-and-characterize-multiple-sclerosis-spinal-cord-lesions-106134https://curecurrent.com/trials/safety-and-efficacy-of-everolimus-afinitor-in-chinese-adult-patients-with-angiomyolipoma-associated-with-tuberous-sclero-106135https://curecurrent.com/trials/dose-escalation-study-of-the-pharmacodynamics-pharmacokinetics-safety-and-immunogenicity-of-bcd-132-in-patients-with-rel-106136https://curecurrent.com/trials/comparative-clinical-trial-to-evaluate-efficacy-safety-and-tolerance-of-bcd-054-and-avonex-for-treatment-of-patients-wit-106137https://curecurrent.com/trials/tecfidera-and-the-gut-microbiota-106138https://curecurrent.com/trials/gilenya-s-impact-on-cognitive-function-and-thalamic-volumes-106139https://curecurrent.com/trials/neural-stem-cell-transplantation-in-multiple-sclerosis-patients-106140https://curecurrent.com/trials/learning-strategies-for-improving-dual-task-performance-in-multiple-sclerosis-106141https://curecurrent.com/trials/app-based-dexterity-training-in-multiple-sclerosis-106142https://curecurrent.com/trials/a-pilot-study-to-evaluate-the-effects-of-everolimus-on-brain-mtor-activity-and-cortical-hyperexcitability-in-tsc-and-fcd-106143https://curecurrent.com/trials/sit-less-or-exercise-more-impact-on-cardiometabolic-health-in-ms-106144https://curecurrent.com/trials/the-effects-of-trunk-stabilization-and-aerobic-trainings-in-multiple-sclerosis-106145https://curecurrent.com/trials/the-impact-of-training-on-sitting-time-and-brain-volumes-in-multiple-sclerosis-106146https://curecurrent.com/trials/longitudinal-effect-of-vitamin-d3-replacement-on-cognitive-performance-and-mri-markers-in-multiple-sclerosis-patients-106147https://curecurrent.com/trials/study-to-evaluate-the-feasibility-of-18f-florbetapir-pet-for-assessment-in-ms-patients-106148https://curecurrent.com/trials/symptoms-and-treatment-assessment-of-ano-rectal-disorders-in-multiple-sclerosis-patients-star-q-106149https://curecurrent.com/trials/promybetaappgame-a-study-to-learn-more-about-the-medication-usage-patient-reported-outcomes-via-the-mybetaapp-and-to-fin-106150https://curecurrent.com/trials/immune-response-to-seasonal-influenza-vaccination-in-multiple-sclerosis-patients-receiving-cladribine-106151https://curecurrent.com/trials/the-role-of-social-and-territorial-inequalities-in-the-management-and-prognosis-of-multiple-sclerosis-106152https://curecurrent.com/trials/teriflunomide-observational-effectiveness-study-106153https://curecurrent.com/trials/a-positive-psychology-intervention-for-patients-with-multiple-sclerosis-106154https://curecurrent.com/trials/physiological-responses-in-experimentally-induced-cognitive-fatigue-in-people-with-multiple-sclerosis-ms-106155https://curecurrent.com/trials/thalamic-nuclei-volumes-in-multiple-sclerosis-106156https://curecurrent.com/trials/sensitivity-of-motor-assessment-in-ms-a-prospective-cohort-study-106157https://curecurrent.com/trials/effect-of-manuel-therapy-on-tonus-proprioseption-and-balance-in-multiple-sclerosis-106158https://curecurrent.com/trials/neurophysiological-assessment-in-patients-with-multiple-sclerosis-106159https://curecurrent.com/trials/study-of-evobrutinib-in-participants-with-rms-106160https://curecurrent.com/trials/study-of-evobrutinib-in-participants-with-relapsing-multiple-sclerosis-rms-106161https://curecurrent.com/trials/sleep-medical-treatment-in-ms-patients-suffering-from-fatigue-106162https://curecurrent.com/trials/imatinib-for-multiple-sclerosis-ms-relapses-106163https://curecurrent.com/trials/humoral-and-t-cell-responses-to-covid-19-vaccination-in-multiple-sclerosis-patients-treated-with-ocrelizumab-treated-wit-106164https://curecurrent.com/trials/electronic-pill-bottle-monitoring-to-promote-medication-adherence-for-people-with-multiple-sclerosis-106165https://curecurrent.com/trials/hydroxychloroquine-in-primary-progressive-multiple-sclerosis-106166https://curecurrent.com/trials/visual-reconstitution-therapy-after-optic-neuritis-106167https://curecurrent.com/trials/nutritional-approaches-in-multiple-sclerosis-106168https://curecurrent.com/trials/metabolic-effects-of-a-green-tea-extract-in-multiple-sclerosis-patients-106169https://curecurrent.com/trials/sunphenon-epigallocatechin-gallate-egcg-in-relapsing-remitting-multiple-sclerosis-sunims-study-106170https://curecurrent.com/trials/evaluation-of-sloan-charts-for-assessment-of-disease-progress-in-multiple-sclerosis-106171https://curecurrent.com/trials/repetitive-deep-transcranial-magnetic-stimulation-in-multiple-sclerosis-106172https://curecurrent.com/trials/sunphenon-in-progressive-forms-of-multiple-sclerosis-106173https://curecurrent.com/trials/histaminergic-basis-of-fatigue-in-multiple-sclerosis-106174https://curecurrent.com/trials/monitoring-natural-killer-cells-in-multiple-sclerosis-patients-treated-with-fingolimod-106175https://curecurrent.com/trials/modification-of-visual-outcomes-after-optic-neuritis-in-cis-or-ms-by-gilenya-moving-study-106176https://curecurrent.com/trials/efficacy-of-vitamin-d-supplementation-in-multiple-sclerosis-evidims-106177https://curecurrent.com/trials/depression-and-immune-function-in-multiple-sclerosis-ms-106178https://curecurrent.com/trials/study-to-assess-resource-utilization-and-quality-of-life-of-patients-with-rrms-treated-with-tecfidera-in-greece-106179https://curecurrent.com/trials/the-validity-and-reliability-of-the-upper-extremity-exercise-testing-uulex-in-patients-with-multiple-sclerosis-106180https://curecurrent.com/trials/telerehabilitation-in-multiple-sclerosis-106181https://curecurrent.com/trials/motor-evoked-potentials-as-a-biomarker-in-alemtuzumab-treated-multiple-sclerosis-patients-106182https://curecurrent.com/trials/the-gut-microbiome-in-adult-multiple-sclerosis-106183https://curecurrent.com/trials/the-effect-of-self-acupressure-application-on-functional-composite-and-quality-of-life-in-multiple-sclerosis-patients-106184https://curecurrent.com/trials/functional-disorders-of-the-musculoskeletal-system-in-people-with-multiple-sclerosis-106185https://curecurrent.com/trials/a-pilot-study-to-characterize-the-biological-effect-of-a-pre-planned-12-week-dose-interruption-of-natalizumab-106186https://curecurrent.com/trials/safety-of-switching-from-rituximab-to-ocrelizumab-in-ms-patients-106187https://curecurrent.com/trials/an-observational-study-to-investigate-the-role-of-b-cells-in-multiple-sclerosis-106188https://curecurrent.com/trials/phase-iia-study-of-ublituximab-in-participants-with-relapsing-forms-of-multiple-sclerosis-106189https://curecurrent.com/trials/effects-of-a-user-centered-exergame-training-on-motor-and-cognitive-functions-in-pwms-106190https://curecurrent.com/trials/core-stability-trunk-position-sense-balance-and-functional-mobility-in-patients-with-multiple-sclerosis-106191https://curecurrent.com/trials/the-effect-of-high-tone-power-therapy-on-fatigue-and-functional-outcomes-in-multiple-sclerosis-106192https://curecurrent.com/trials/safety-study-of-human-neural-stem-cells-injections-for-secondary-progressive-multiple-sclerosis-patients-106193https://curecurrent.com/trials/acthar-gel-for-multiple-sclerosis-that-keeps-getting-better-and-worse-rrms-106194https://curecurrent.com/trials/a-study-of-the-effectiveness-of-fampridine-in-improving-upper-limb-function-in-ms-106195https://curecurrent.com/trials/efficacy-of-early-harvest-olive-oil-in-cognition-of-primary-ppms-or-secondary-spms-progressive-multiple-sclerosis-106196https://curecurrent.com/trials/the-treatment-of-amyotrophic-lateral-sclerosis-with-huollingshengji-granules-106197https://curecurrent.com/trials/clinical-isolation-syndrome-of-spinal-cord-and-multiple-sclerosis-106198https://curecurrent.com/trials/efficacy-and-tolerability-of-sti571-imatinib-mesylate-for-the-treatment-of-fibrosis-in-participants-with-systemic-sclero-106199https://curecurrent.com/trials/life-style-exercise-and-activity-package-for-people-living-with-progressive-ms-106200https://curecurrent.com/trials/regular-exercise-improves-physical-capacity-and-promotes-neurotrophins-in-patients-with-multiple-sclerosis-106201https://curecurrent.com/trials/investigation-of-hand-functions-and-related-parameters-in-people-with-multiple-sclerosis-106202https://curecurrent.com/trials/self-help-for-fatigue-in-multiple-sclerosis-106203https://curecurrent.com/trials/multiple-sclerosis-and-voiding-symptoms-how-to-assess-106204https://curecurrent.com/trials/dexpramipexole-japanese-pk-study-106205https://curecurrent.com/trials/tele-assessment-and-face-to-face-evaluation-of-functional-gait-assessment-in-multiple-sclerosis-106206https://curecurrent.com/trials/sf-qualiveen-turkish-validity-and-reliability-study-106207https://curecurrent.com/trials/safety-and-effectiveness-of-cinnomer-glatiramer-acetate-in-multiple-sclerosis-ms-treatment-in-iran-106208https://curecurrent.com/trials/the-minnesota-manual-dexterity-test-as-a-measure-of-hand-function-in-multiple-sclerosis-106209https://curecurrent.com/trials/french-adaptation-of-the-california-card-sorting-task-ccst-in-multiple-sclerosis-106210https://curecurrent.com/trials/home-based-infusions-for-ocrelizumab-106211https://curecurrent.com/trials/the-added-value-of-cognition-targeted-exercise-versus-symptom-targeted-exercise-for-multiple-sclerosis-fatigue-106212https://curecurrent.com/trials/eeg-and-tms-based-biomarkers-of-als-ms-and-ftd-106213https://curecurrent.com/trials/phase-3-study-of-dexpramipexole-in-als-106214https://curecurrent.com/trials/aerobic-exercise-and-brain-health-in-multiple-sclerosis-106215https://curecurrent.com/trials/theory-based-intervention-program-to-support-physical-activity-for-individuals-with-multiple-sclerosis-a-case-series-106216https://curecurrent.com/trials/study-to-assess-oct-rnfl-and-gcl-in-ms-patients-106217https://curecurrent.com/trials/pilot-investigation-to-evaluate-flowox2-0-for-experimental-treatment-of-spasticity-106218https://curecurrent.com/trials/the-possible-neuroprotective-effect-of-ocrelizumab-via-vegf-protein-expression-in-relapsing-multiple-sclerosis-patients-106219https://curecurrent.com/trials/proof-of-mechanism-study-of-gsk2330811-in-diffuse-cutaneous-systemic-sclerosis-106220https://curecurrent.com/trials/idebenone-for-primary-progressive-multiple-sclerosis-106221https://curecurrent.com/trials/treatment-of-sleep-disordered-breathing-in-patients-with-sci-106222https://curecurrent.com/trials/study-by-magnetic-resonance-imaging-in-the-progressive-forms-of-multiple-sclerosis-106223https://curecurrent.com/trials/clinical-study-to-compare-the-efficacy-and-safety-of-ponesimod-to-placebo-in-subjects-with-active-relapsing-multiple-scl-106224https://curecurrent.com/trials/the-effects-of-respiratory-based-telerehabilitaion-in-patients-with-ms-106225https://curecurrent.com/trials/sport-rehabilitation-and-nutrition-in-multiple-sclerosis-the-linus-project-106226https://curecurrent.com/trials/the-effect-of-cervical-mobilization-on-balance-and-spasticity-in-multiple-sclerosis-individuals-106227https://curecurrent.com/trials/a-social-emotion-regulation-intervention-in-ms-106228https://curecurrent.com/trials/the-multiple-sclerosis-continuous-quality-improvement-mscqi-collaborative-106229https://curecurrent.com/trials/comparison-of-robot-assisted-gait-training-and-conventional-therapy-in-multiple-sclerosis-patients-106230https://curecurrent.com/trials/neuromuscular-electrical-stimulation-and-mobility-in-multiple-sclerosis-106231https://curecurrent.com/trials/emdr-for-depressed-people-with-multiple-sclerosis-106232https://curecurrent.com/trials/a-tom-training-for-people-with-multiple-sclerosis-an-efficacy-study-106233https://curecurrent.com/trials/bx-1-in-spasticity-due-to-multiple-sclerosis-106234https://curecurrent.com/trials/motor-evoked-potentials-with-modified-facilitation-technique-106235https://curecurrent.com/trials/a-clinical-study-to-test-how-effective-and-safe-glpg1690-is-for-participants-with-systemic-sclerosis-106236https://curecurrent.com/trials/topical-everolimus-in-patients-with-tuberous-sclerosis-complex-106237https://curecurrent.com/trials/waking-hypnosis-in-the-treatment-of-ms-related-fatigue-106238https://curecurrent.com/trials/covid-19-and-multiple-sclerosis-disease-modifying-therapies-106239https://curecurrent.com/trials/internet-based-physical-activity-promotion-and-exercise-prescription-for-people-with-multiple-sclerosis-106240https://curecurrent.com/trials/feasibility-study-of-transcutaneous-tibial-nerve-stimulation-for-urinary-symptoms-in-people-with-multiple-sclerosis-106241https://curecurrent.com/trials/gm604-phase-2a-randomized-double-blind-placebo-controlled-pilot-trial-in-amyotrophic-lateral-disease-als-106242https://curecurrent.com/trials/long-term-safety-and-tolerability-of-0-5-mg-fingolimod-in-patients-with-relapsing-forms-of-multiple-sclerosis-106243https://curecurrent.com/trials/rituximab-long-term-dose-trial-in-multiple-sclerosis-ridose-ms-106244https://curecurrent.com/trials/the-effect-of-dietary-salt-intake-on-immune-function-in-patients-with-multiple-sclerosis-106245https://curecurrent.com/trials/effects-of-lutein-supplementation-on-cognition-and-mpod-in-multiple-sclerosis-patients-106246https://curecurrent.com/trials/3-meter-backwards-walk-test-and-multiple-sclerosis-106247https://curecurrent.com/trials/retrospective-study-on-registry-data-to-evaluate-the-impact-of-ocrelizumab-used-in-routine-care-in-patients-with-rrms-106248https://curecurrent.com/trials/physiotherapist-guided-home-exercise-in-moderate-to-severe-ms-106249https://curecurrent.com/trials/prevalence-of-fabry-disease-in-a-defined-population-at-risk-patients-formerly-diagnosed-with-multiple-sclerosis-106250https://curecurrent.com/trials/cortical-lesions-in-patients-with-multiple-sclerosis-106251https://curecurrent.com/trials/a-pilot-trial-to-test-the-feasibility-of-prolonged-fasting-and-ketogenic-diet-in-relapsing-remitting-multiple-sclerosis-106252https://curecurrent.com/trials/home-exercise-telerehabiliation-for-ms-106253https://curecurrent.com/trials/the-effects-of-relaxation-techniques-on-pain-fatigue-and-kinesiophobia-in-multiple-sclerosis-patients-a-three-arms-rando-106254https://curecurrent.com/trials/the-relationship-between-fatigue-and-physical-activity-level-in-patients-with-multiple-sclerosis-106255https://curecurrent.com/trials/imaging-evaluation-of-central-nervous-autoimmune-diseases-106256https://curecurrent.com/trials/effects-of-repeated-mesenchymal-stem-cells-msc-in-patients-with-progressive-multiple-sclerosis-106257https://curecurrent.com/trials/repetitive-transorbital-alternating-current-stimulation-in-acute-autoimmune-optic-neuritis-106258https://curecurrent.com/trials/mesenchymal-stem-cells-for-the-treatment-of-ms-106259https://curecurrent.com/trials/rapalogues-for-autism-phenotype-in-tsc-a-feasibility-study-106260https://curecurrent.com/trials/linking-cognitive-functioning-to-multimodal-imaging-in-multiple-sclerosis-ms-106261https://curecurrent.com/trials/biomarkers-and-disease-activity-in-patients-treated-with-teriflunomide-aubagio-106262https://curecurrent.com/trials/quantitative-magnetic-resonance-imaging-mri-sub-study-of-ms-paths-106263https://curecurrent.com/trials/emotion-regulation-skills-training-for-individuals-with-ms-and-their-support-partners-106264https://curecurrent.com/trials/mindfulness-for-newly-diagnosed-multiple-sclerosis-106265https://curecurrent.com/trials/oral-cladribine-in-early-multiple-sclerosis-ms-106266https://curecurrent.com/trials/comparison-of-1-5t-vs-3t-protocols-after-treatment-with-glatiramer-acetate-ga-106267https://curecurrent.com/trials/cognitive-behavioural-therapy-software-for-the-treatment-of-depression-in-people-with-multiple-sclerosis-106268https://curecurrent.com/trials/behavior-cognitive-therapy-on-fatigue-impact-in-ms-patients-106269https://curecurrent.com/trials/post-contrast-3d-se-t1-versus-coronal-se-t1-wi-mri-in-detecting-optic-neuritis-cocon-106270https://curecurrent.com/trials/3d-flair-versus-coronal-t2-wi-mri-in-detecting-optic-neuritis-flacon-106271https://curecurrent.com/trials/comprehensive-fall-prevention-and-detection-in-multiple-sclerosis-106272https://curecurrent.com/trials/a-study-to-characterize-subcutaneous-or-intravenous-alemtuzumab-in-patients-with-progressive-multiple-sclerosis-106273https://curecurrent.com/trials/patient-research-cohort-rapidly-evolving-multiple-sclerosis-106274https://curecurrent.com/trials/exercise-and-brain-health-in-ms-106275https://curecurrent.com/trials/kitams-kinesio-tape-and-physical-function-in-persons-with-multiples-sclerosis-106276https://curecurrent.com/trials/rotating-frame-relaxation-imaging-in-patients-with-multiple-sclerosis-106277https://curecurrent.com/trials/dreams-digital-biomarkers-for-multiple-sclerosis-106278https://curecurrent.com/trials/low-fat-diet-for-fatigue-in-ms-106279https://curecurrent.com/trials/mirna-biomarkers-in-multiple-sclerosis-106280https://curecurrent.com/trials/photobiomodulation-therapy-in-persons-with-multiple-sclerosis-106281https://curecurrent.com/trials/effect-of-coduse-balance-training-and-step-square-exercises-on-risk-of-fall-in-multiple-sclerosis-106282https://curecurrent.com/trials/efficacy-and-safety-of-arbaclofen-placarbil-in-subjects-with-spasticity-due-to-multiple-sclerosis-106283https://curecurrent.com/trials/longitudinal-analysis-and-sample-collection-to-evaluate-pml-risk-host-markers-for-pml-risk-host-markers-for-pml-risk-106284https://curecurrent.com/trials/effects-of-digital-pelvic-floor-muscle-training-in-patients-with-multiple-sclerosis-having-lower-urinary-tract-symptoms-106285https://curecurrent.com/trials/intervention-for-employed-women-with-multiple-sclerosis-106286https://curecurrent.com/trials/physical-telerehabilitation-in-multiple-sclerosis-106287https://curecurrent.com/trials/quality-of-life-assessment-between-stroke-and-multiple-sclerosis-patients-of-the-same-age-range-106288https://curecurrent.com/trials/ia-or-pe-what-is-the-best-treatment-option-of-steroid-refractory-neurological-autoimmune-diseases-106289https://curecurrent.com/trials/use-of-cellular-stromal-vascular-fraction-in-multiple-sclerosis-autoimmune-inflammatory-neurologic-conditions-106290https://curecurrent.com/trials/analgesic-effect-of-repetitive-transcranial-magnetic-stimulation-rtms-for-central-neuropathic-pain-in-multiple-sclerosis-106291https://curecurrent.com/trials/effect-of-ankle-foot-orthoses-on-balance-confidence-106292https://curecurrent.com/trials/the-3-meter-backward-walk-test-in-individuals-with-multiple-sclerosis-106293https://curecurrent.com/trials/reliability-and-validity-of-the-glittre-activities-of-daily-living-test-in-multiple-sclerosis-patients-106294https://curecurrent.com/trials/efficacy-and-safety-study-of-ozanimod-in-relapsing-multiple-sclerosis-106295https://curecurrent.com/trials/efficacy-and-safety-study-of-ozanimod-rpc1063-in-relapsing-multiple-sclerosis-patients-106296https://curecurrent.com/trials/impaired-glucose-tolerance-and-cognition-in-ms-106297https://curecurrent.com/trials/default-mode-network-in-multiple-sclerosis-106298https://curecurrent.com/trials/the-effect-of-cognitive-group-exercise-combined-with-physical-exercise-in-ms-106299https://curecurrent.com/trials/long-term-open-label-multicenter-study-assessing-long-term-cardiovascular-risks-106300https://curecurrent.com/trials/retrospective-observational-study-about-long-term-effect-of-fampridine-in-patients-with-multiple-sclerosis-106301https://curecurrent.com/trials/safety-study-of-gnbac1-in-multiple-sclerosis-patients-106302https://curecurrent.com/trials/wireless-implantable-tibial-nerve-stimulator-system-ecoin-for-the-treatment-of-refractory-lower-urinary-tract-symptoms-i-106303https://curecurrent.com/trials/early-biomarkers-of-autism-in-infants-with-tuberous-sclerosis-complex-tsc-106304https://curecurrent.com/trials/short-and-long-term-multiple-outcomes-in-persons-with-multiple-sclerosis-treated-by-fampridine-106305https://curecurrent.com/trials/preventive-program-in-multiple-sclerosis-106306https://curecurrent.com/trials/an-open-label-long-term-study-of-pregabalin-for-the-treatment-of-central-neuropathic-pain-106307https://curecurrent.com/trials/immune-profiling-during-ocrelizumab-treatment-in-multiple-sclerosis-106308https://curecurrent.com/trials/adrenocorticotropic-hormone-acth-effects-on-myelination-in-subjects-with-ms-106309https://curecurrent.com/trials/dynamic-balance-training-in-multiple-sclerosis-106310https://curecurrent.com/trials/social-cognition-in-multiple-sclerosis-from-a-study-of-eye-movement-and-gaze-strategies-using-video-oculography-106311https://curecurrent.com/trials/effect-of-cervical-mobilization-on-balance-and-plantar-pressure-distribution-in-multiple-sclerosis-106312https://curecurrent.com/trials/melatonin-for-sleep-in-ms-106313https://curecurrent.com/trials/maximizing-outcome-of-multiple-sclerosis-transplantation-106314https://curecurrent.com/trials/sunlight-study-online-support-groups-for-ms-to-address-covid-19-106315https://curecurrent.com/trials/the-effects-of-pilates-based-core-stabilization-training-in-multiple-sclerosis-106316https://curecurrent.com/trials/teriflunomide-tecfidera-lmce-106317https://curecurrent.com/trials/a-study-to-assess-the-effect-of-a-single-infusion-of-vay736-on-disease-activity-in-patients-with-relapsing-remitting-mul-106318https://curecurrent.com/trials/effect-of-adrenocorticotropin-injection-with-weekly-interferon-beta-in-patients-with-relapsing-remitting-multiple-sclero-106319https://curecurrent.com/trials/evaluation-of-patient-retention-of-fingolimod-vs-currently-approved-disease-modifying-therapy-in-patients-with-relapsing-106320https://curecurrent.com/trials/bg00012-monotherapy-safety-and-efficacy-extension-study-in-multiple-sclerosis-ms-106321https://curecurrent.com/trials/effect-of-interferon-beta-1a-avonex-on-changes-of-non-conventional-mri-measures-in-patients-with-ms-106322https://curecurrent.com/trials/dimethyl-fumarate-treatment-of-primary-progressive-multiple-sclerosis-106323https://curecurrent.com/trials/bright-light-therapy-as-possible-treatment-option-for-ms-fatigue-106324https://curecurrent.com/trials/observational-study-in-multiple-sclerosis-patients-treated-with-autologous-hematopoietic-stem-cell-transplantation-106325https://curecurrent.com/trials/qax576-in-patients-with-pulmonary-fibrosis-secondary-to-systemic-sclerosis-106326https://curecurrent.com/trials/clinical-effect-of-botulinum-toxin-type-a-in-treatment-of-spasticity-106327https://curecurrent.com/trials/assessing-the-induction-of-long-term-immune-regulation-following-treatment-with-lemtrada-alemtuzumab-106328https://curecurrent.com/trials/efficacy-of-bipams-for-restless-legs-syndrome-in-adults-with-multiple-sclerosis-a-pilot-study-106329https://curecurrent.com/trials/clarity-extension-study-106330https://curecurrent.com/trials/study-of-ozanimod-rpc1063-in-relapsing-multiple-sclerosis-ms-106331https://curecurrent.com/trials/evaluate-safety-tolerability-in-portuguese-participants-with-rrms-transitioning-from-current-therapy-106332https://curecurrent.com/trials/multiple-doses-of-anti-nogo-a-in-relapsing-forms-of-multiple-sclerosis-106333https://curecurrent.com/trials/itbs-study-for-depression-in-patients-with-multiple-sclerosis-106334https://curecurrent.com/trials/effect-of-md1003-in-progressive-multiple-sclerosis-spi2-106335https://curecurrent.com/trials/effect-of-behavioral-therapy-versus-interferential-current-on-bladder-dysfunction-in-patients-with-multiple-sclerosis-106336https://curecurrent.com/trials/intermittent-hypoxia-intervention-in-ms-patients-106337https://curecurrent.com/trials/immunoadsorption-versus-high-dose-intravenous-corticosteroids-in-relapsing-multiple-sclerosis-106338https://curecurrent.com/trials/gta-meg-as-a-biomarker-for-cognition-in-ms-106339https://curecurrent.com/trials/preventive-use-of-corticosteroids-during-the-post-partum-in-relapsing-ms-patients-copp-ms-106340https://curecurrent.com/trials/biological-activity-and-safety-of-low-dose-il2-in-relapsing-remitting-multiple-sclerosis-106341https://curecurrent.com/trials/the-prelims-feasibility-trial-106342https://curecurrent.com/trials/mechanistic-studies-of-phase-iii-trial-with-baf312-in-secondary-progressive-multiple-sclerosis-106343https://curecurrent.com/trials/jasper-early-intervention-for-tuberous-sclerosis-106344https://curecurrent.com/trials/improving-mobility-and-reducing-fatigue-in-people-with-multiple-sclerosis-by-electrical-stimulation-therapy-106345https://curecurrent.com/trials/efit-an-internet-based-intervention-to-increase-physical-activity-in-persons-with-ms-106346https://curecurrent.com/trials/a-multi-center-controlled-screening-trial-of-safety-and-efficacy-of-lithium-carbonate-in-subjects-with-amyotrophic-later-106347https://curecurrent.com/trials/topical-rapamycin-to-erase-angiofibromas-in-tsc-106348https://curecurrent.com/trials/digital-cognition-in-multiple-sclerosis-106349https://curecurrent.com/trials/effects-of-ten-weeks-power-training-on-neuromuscular-performance-heart-rate-variability-sleep-quality-and-mobility-in-pe-106350https://curecurrent.com/trials/impact-of-the-arrival-on-the-french-market-of-new-first-line-oral-treatments-on-the-delay-between-ms-onset-and-first-dis-106351https://curecurrent.com/trials/characteristics-of-intestinal-dysfunction-in-patients-with-multiple-sclerosis-106352https://curecurrent.com/trials/clinical-trial-assessing-the-herv-w-env-antagonist-gnbac1-for-efficacy-in-ms-106353https://curecurrent.com/trials/longitudinal-therapeutically-non-interventional-study-of-msrv-env-burden-in-normal-population-106354https://curecurrent.com/trials/longitudinal-therapeutically-non-interventional-study-of-msrv-env-burden-in-patients-with-multiple-sclerosis-disease-106355https://curecurrent.com/trials/treatment-of-fatigue-with-methylphenidate-modafinil-and-amantadine-in-multiple-sclerosis-106356https://curecurrent.com/trials/assessing-the-herv-w-env-antagonist-gnbac1-for-evaluation-in-an-open-label-long-term-safety-study-in-patients-with-multi-106357https://curecurrent.com/trials/safety-study-of-gnbac1-monoclonal-antibody-in-healthy-male-volunteers-106358https://curecurrent.com/trials/single-ascending-doses-study-with-gnbac1-in-healthy-male-volunteers-106359https://curecurrent.com/trials/first-in-human-study-with-gnbac1-in-healthy-volunteers-106360https://curecurrent.com/trials/medical-education-for-better-multiple-sclerosis-outcomes-106361https://curecurrent.com/trials/discontinuing-disease-modifying-therapies-in-stable-relapsing-onset-multiple-sclerosis-dot-ms-106362https://curecurrent.com/trials/qigong-for-multiple-sclerosis-a-feasibility-study-106363https://curecurrent.com/trials/a-phase-2-study-of-cladribine-add-on-to-interferon-beta-ifn-beta-therapy-in-multiple-sclerosis-ms-subjects-with-active-d-106364https://curecurrent.com/trials/effects-of-ten-weeks-progressive-resistance-training-on-neuromuscular-performance-mobility-heart-rate-variability-and-sl-106365https://curecurrent.com/trials/histaminergic-basis-of-central-fatigue-in-multiple-sclerosis-a-novel-approach-106366https://curecurrent.com/trials/fecal-microbiota-transplantation-fmt-in-multiple-sclerosis-106367https://curecurrent.com/trials/epley-manoeuvre-in-participants-with-multiple-sclerosis-diagnosed-from-benign-paroxysmal-positional-vertigo-106368https://curecurrent.com/trials/the-utilization-of-yoga-as-a-therapeutic-tool-to-promote-physical-activity-behavior-change-and-improved-postural-control-106369https://curecurrent.com/trials/effects-of-dalfampridine-on-cognition-in-multiple-sclerosis-106370https://curecurrent.com/trials/transitioning-to-a-valve-gated-intrathecal-drug-delivery-system-idds-106371https://curecurrent.com/trials/acceptance-based-telephone-support-when-transitioning-to-spms-106372https://curecurrent.com/trials/study-of-induction-therapy-with-mitoxantrone-and-plasmapheresis-to-treat-aggressive-multiple-sclerosis-106373https://curecurrent.com/trials/everolimus-for-cancer-with-tsc1-or-tsc2-mutation-106374https://curecurrent.com/trials/a-study-to-evaluate-efficacy-safety-and-tolerability-of-ck-2127107-in-patients-with-amyotrophic-lateral-sclerosis-als-106375https://curecurrent.com/trials/aerobic-exercises-for-multiple-sclerosis-106376https://curecurrent.com/trials/ventilatory-investigation-of-tirasemtiv-and-assessment-of-longitudinal-indices-after-treatment-for-a-year-106377https://curecurrent.com/trials/virtual-reality-approach-in-multiple-sclerosis-106378https://curecurrent.com/trials/study-and-treatment-of-visual-dysfunction-and-motor-fatigue-in-multiple-sclerosis-106379https://curecurrent.com/trials/the-relationship-between-kinesiophobia-physical-activity-balance-and-fear-of-fall-in-ms-patients-106380https://curecurrent.com/trials/a-cross-sectional-study-of-msdx-complex-1-as-a-marker-for-active-disease-in-multiple-sclerosis-106381https://curecurrent.com/trials/a-study-of-msdx-complex-1-as-a-marker-for-therapy-response-in-multiple-sclerosis-106382https://curecurrent.com/trials/excitotoxicity-markers-and-the-clinical-radiological-progression-after-a-demyelinating-event-a-prospective-pilot-study-106383https://curecurrent.com/trials/e-support-groups-in-multiple-sclerosis-106384https://curecurrent.com/trials/tolerability-of-acthar-for-the-treatment-of-multiple-sclerosis-in-relapses-tams-106385https://curecurrent.com/trials/difference-in-efficacy-of-natalizumab-versus-fingolimod-for-the-treatment-of-multiple-sclerosis-106386https://curecurrent.com/trials/exercise-in-multiple-sclerosis-106387https://curecurrent.com/trials/coaching-and-activity-tracking-in-multiple-sclerosis-a-pilot-study-106388https://curecurrent.com/trials/ketamine-for-treatment-of-ms-fatigue-106389https://curecurrent.com/trials/preventing-job-loss-using-acceptance-and-commitment-therapy-in-vocational-rehabilitation-106390https://curecurrent.com/trials/stem-cell-therapy-for-patients-with-multiple-sclerosis-failing-alternate-approved-therapy-a-randomized-study-106391https://curecurrent.com/trials/reducing-symptoms-of-multiple-sclerosis-using-non-invasive-neuromodulation-106392https://curecurrent.com/trials/motor-skill-acquisition-between-individuals-with-neurological-disorders-and-healthy-individuals-106393https://curecurrent.com/trials/a-study-of-gdc-0134-to-determine-initial-safety-tolerability-and-pharmacokinetic-parameters-in-participants-with-amyotro-106394https://curecurrent.com/trials/efficacy-of-pons-in-reducing-symptoms-of-multiple-sclerosis-106395https://curecurrent.com/trials/additional-effect-of-intrapulmonary-percussive-ventilation-ipv-on-respiration-in-people-with-multiple-sclerosis-ms-106396https://curecurrent.com/trials/can-transcranial-direct-current-stimulation-improve-ambulation-and-fatigue-resistance-in-people-with-ms-106397https://curecurrent.com/trials/physiologic-volume-and-atrophy-of-brain-and-spinal-cord-measured-by-magnetic-resonance-imaging-106398https://curecurrent.com/trials/hypnosis-and-direct-autonomic-experience-influence-on-chronic-symptoms-106399https://curecurrent.com/trials/safety-tolerability-and-activity-study-of-ibudilast-in-subjects-with-progressive-multiple-sclerosis-106400https://curecurrent.com/trials/evaluation-and-neural-basis-of-communication-in-patients-with-multiple-sclerosis-106401https://curecurrent.com/trials/cerebrovascular-changes-in-multiple-sclerosis-patients-106402https://curecurrent.com/trials/nutritional-counselling-for-patients-at-kasr-alainy-multiple-sclerosis-clinic-an-intervention-study-106403https://curecurrent.com/trials/neuroproprioceptive-facilitation-inhibition-and-brain-plasticity-106404https://curecurrent.com/trials/emotional-processing-in-multiple-sclerosis-clinically-isolated-syndrome-a-neuropsychological-fmri-study-106405https://curecurrent.com/trials/a-tsec-for-symptom-management-in-menopausal-women-with-multiple-sclerosis-106406https://curecurrent.com/trials/a-tolerability-study-of-alks-8700-in-subjects-with-relapsing-remitting-multiple-sclerosis-rrms-evolve-ms-2-106407https://curecurrent.com/trials/ph-weighted-mri-in-multiple-sclerosis-a-surrogate-marker-of-tissue-metabolic-stress-106408https://curecurrent.com/trials/rituximab-induced-hypogammaglobulinemia-in-multiple-sclerosis-106409https://curecurrent.com/trials/remediation-of-emotional-processing-deficits-in-ms-106410https://curecurrent.com/trials/patient-acceptable-symptomatic-state-and-minimal-clinically-important-difference-of-the-fatigue-in-multiple-sclerosis-se-106411https://curecurrent.com/trials/local-vibration-in-multiple-sclerosis-patients-106412https://curecurrent.com/trials/brain-activity-changes-following-neuroproprioceptive-physiotherapy-in-multiple-sclerosis-106413https://curecurrent.com/trials/a-study-to-evaluate-the-safety-of-administering-ocrelizumab-per-a-shorter-infusion-protocol-in-participants-with-primary-106414https://curecurrent.com/trials/immunodeficiency-in-ms-106415https://curecurrent.com/trials/investigation-of-fatigue-physical-activity-sleep-quality-and-anxiety-levels-106416https://curecurrent.com/trials/behavioural-activation-for-low-mood-in-multiple-sclerosis-106417https://curecurrent.com/trials/aspirin-as-an-add-on-treatment-of-refractory-epilepsy-in-tuberous-sclerosis-complex-106418https://curecurrent.com/trials/stat4-in-multiple-sclerosis-by-pcr-and-flow-cytometry-106419https://curecurrent.com/trials/telerehabilitation-vs-supervised-exercises-in-ms-106420https://curecurrent.com/trials/relationship-between-pain-anxiety-and-fatigue-and-knee-position-sense-balance-and-dual-task-performance-during-menstrual-106421https://curecurrent.com/trials/underlying-causes-and-related-factors-and-rehabilitation-approaches-106422https://curecurrent.com/trials/art-for-ms-controlled-trial-106423https://curecurrent.com/trials/calorie-restriction-in-multiple-sclerosis-patients-106424https://curecurrent.com/trials/remediation-of-emotional-deficits-in-multiple-sclerosis-and-traumatic-brain-injury-106425https://curecurrent.com/trials/a-clinical-trial-of-pimozide-in-patients-with-amyotrophic-lateral-sclerosis-als-106426https://curecurrent.com/trials/sonification-embodied-associations-106427https://curecurrent.com/trials/position-sense-balance-and-dual-task-performance-at-the-menstrual-cycle-in-females-with-multiple-sclerosis-106428https://curecurrent.com/trials/a-study-of-ocrelizumab-in-participants-with-relapsing-remitting-multiple-sclerosis-rrms-who-have-had-a-suboptimal-respon-106429https://curecurrent.com/trials/psychometric-properties-upper-limb-function-measures-multiple-sclerosis-106430https://curecurrent.com/trials/coagulation-complement-activation-and-cerebral-hypoperfusion-in-relapsing-remitting-multiple-sclerosis-106431https://curecurrent.com/trials/walk-with-me-a-mobile-application-to-improve-walking-in-persons-with-ms-106432https://curecurrent.com/trials/wearable-biosensor-to-track-and-quantify-limb-dysfunction-in-multiple-sclerosis-patients-106433https://curecurrent.com/trials/exergames-balance-program-in-neurorehabilitation-106434https://curecurrent.com/trials/light-therapy-as-treatment-for-fatigue-in-multiple-sclerosis-106435https://curecurrent.com/trials/muscle-vibration-in-ms-to-improve-walking-106436https://curecurrent.com/trials/pilot-study-of-transcranial-direct-current-stimulation-tdcs-106437https://curecurrent.com/trials/physical-therapy-and-neuroactive-steroids-therapy-does-not-modulate-serum-level-of-neuroactive-steroids-106438https://curecurrent.com/trials/study-of-exercise-on-impact-of-cognitive-functioning-in-multiple-sclerosis-patients-106439https://curecurrent.com/trials/the-reliability-and-validity-of-the-functional-reach-test-in-patients-with-multiple-sclerosis-106440https://curecurrent.com/trials/symptomatic-trigeminal-neuralgia-attributed-to-multiple-sclerosis-a-prospective-study-in-60-patients-106441https://curecurrent.com/trials/myotonometer-analyses-of-muscles-in-multiple-sclerosis-patients-with-dysphagia-106442https://curecurrent.com/trials/sensor-based-technology-for-upper-limb-rehabilitation-106443https://curecurrent.com/trials/the-effect-of-neurorehabilitation-therapy-on-postural-control-mobility-and-quality-of-life-in-multiple-sclerosis-patient-106444https://curecurrent.com/trials/internet-based-physical-activity-promotion-and-exercise-prescription-for-people-with-multiple-sclerosis-feasibility-stud-106445https://curecurrent.com/trials/regulation-of-lipid-metabolism-in-autoimmune-disease-multiple-sclerosis-106446https://curecurrent.com/trials/carnosine-loading-and-periodized-training-in-ms-and-hc-106447https://curecurrent.com/trials/the-effects-of-muscles-strength-on-physical-performance-in-patients-with-multiple-sclerosis-106448https://curecurrent.com/trials/efficacy-and-safety-of-masitinib-in-the-treatment-of-progressive-multiple-sclerosis-106449https://curecurrent.com/trials/effects-of-acthar-on-recovery-from-cognitive-relapses-in-ms-106450https://curecurrent.com/trials/tdcs-and-cognition-in-adults-with-multiple-sclerosis-or-encephalitis-106451https://curecurrent.com/trials/adherence-to-treatment-with-tecfidera-in-multiple-sclerosis-patients-106452https://curecurrent.com/trials/spinal-cord-analysis-in-multiple-sclerosis-106453https://curecurrent.com/trials/study-of-safety-tolerability-efficacy-of-ck-2017357-in-amyotrophic-lateral-sclerosis-als-106454https://curecurrent.com/trials/a-study-of-neurovax-a-novel-therapeutic-tcr-peptide-vaccine-for-pediatric-multiple-sclerosis-106455https://curecurrent.com/trials/study-of-montelukast-on-gastrointestinal-tolerability-in-patients-with-relapsing-forms-of-multiple-sclerosis-receiving-t-106456https://curecurrent.com/trials/mental-practice-and-manipulative-skills-training-in-multiple-sclerosis-106457https://curecurrent.com/trials/neurx-diaphram-pacing-system-dps-use-in-amyotrophic-lateral-sclerosis-als-106458https://curecurrent.com/trials/ms-smart-multiple-sclerosis-secondary-progressive-multi-arm-randomisation-trial-106459https://curecurrent.com/trials/oral-carnosine-for-neuromuscular-performance-in-multiple-sclerosis-106460https://curecurrent.com/trials/upper-limb-telerehabilitation-with-virtual-reality-in-multiple-sclerosis-106461https://curecurrent.com/trials/pilot-and-feasibility-trial-of-a-telehealth-dietary-intervention-for-ms-106462https://curecurrent.com/trials/functional-electrical-stimulation-for-individuals-with-secondary-progressive-multiple-sclerosis-106463https://curecurrent.com/trials/a-study-evaluating-the-effectiveness-of-tecfidera-dimethyl-fumarate-on-multiple-sclerosis-ms-disease-activity-and-patien-106464https://curecurrent.com/trials/muscle-architecture-of-lower-extremity-in-multiple-sclerosis-106465https://curecurrent.com/trials/preventing-utis-in-chronic-neurogenic-bladder-dysfunction-mix-methods-106466https://curecurrent.com/trials/phase-1-dose-escalation-and-pk-study-of-cu-ii-atsm-in-als-mnd-106467https://curecurrent.com/trials/autologous-bone-marrow-derived-stem-cells-for-the-treatment-of-multiple-sclerosis-106468https://curecurrent.com/trials/recall-enhancement-through-treatment-with-atomoxetine-in-ms-retain-ms-106469https://curecurrent.com/trials/exercise-to-manage-fatigue-in-progressive-multiple-sclerosis-106470https://curecurrent.com/trials/a-study-of-neurovax-a-therapeutic-tcr-peptide-vaccine-for-spms-of-multiple-sclerosis-106471https://curecurrent.com/trials/a-study-of-neurovax-a-novel-therapeutic-tcr-peptide-vaccine-for-spms-of-multiple-sclerosis-106472https://curecurrent.com/trials/dermatologic-patterns-of-tuberous-sclerosis-patients-and-somatic-mutation-relationship-106473https://curecurrent.com/trials/microrna-150-and-microrna-155-in-multiple-sclerosis-106474https://curecurrent.com/trials/multiple-sclerosis-chi3l1-and-treatment-efficacy-106475https://curecurrent.com/trials/transcutaneous-direct-current-stimulation-of-the-spinal-cord-for-treatment-of-spasticity-in-multiple-sclerosis-106476https://curecurrent.com/trials/safety-and-efficacy-of-intravenous-autologous-mesenchymal-stem-cells-for-ms-a-phase-2-proof-of-concept-study-106477https://curecurrent.com/trials/diagnose-using-the-central-vein-sign-106478https://curecurrent.com/trials/allogenic-mesenchymal-stem-cells-and-physical-therapy-for-ms-treatment-106479https://curecurrent.com/trials/a-3-year-multi-center-study-to-describe-changes-of-oct-parameters-under-treatment-with-gilenya-106480https://curecurrent.com/trials/treatment-of-multiple-sclerosis-and-neuromyelitis-optica-with-regulatory-dendritic-cell-clinical-trial-phase-1-b-106481https://curecurrent.com/trials/mindfulness-meditation-in-treating-insomnia-in-multiple-sclerosis-106482https://curecurrent.com/trials/safety-tolerability-and-mechanism-of-action-of-boswellic-acids-ba-in-multiple-sclerosis-saba-106483https://curecurrent.com/trials/domperidone-in-secondary-progressive-multiple-sclerosis-spms-106484https://curecurrent.com/trials/acute-intermittent-hypoxia-in-persons-with-multiple-sclerosis-106485https://curecurrent.com/trials/mr-guided-focused-ultrasound-mrgfus-for-the-management-of-tremor-in-patients-with-multiple-sclerosis-106486https://curecurrent.com/trials/the-novel-use-of-treadmill-plus-music-in-ms-patients-gate-rehabilitation-106487https://curecurrent.com/trials/gene-expression-profiles-in-multiple-sclerosis-ms-106488https://curecurrent.com/trials/intellectual-enrichment-to-build-cognitive-reserve-in-ms-106489https://curecurrent.com/trials/speed-of-processing-training-to-improve-cognition-in-multiple-sclerosis-106490https://curecurrent.com/trials/glatiramer-acetate-copaxone-study-to-follow-participants-from-the-first-original-study-for-safety-and-effectiveness-106491https://curecurrent.com/trials/quantitative-fatigue-and-muscle-performance-in-multiple-sclerosis-106492https://curecurrent.com/trials/periodized-rehabilitation-and-beta-alanine-supplementation-in-multiple-sclerosis-106493https://curecurrent.com/trials/complementary-and-alternative-care-in-multiple-sclerosis-106494https://curecurrent.com/trials/therapeutic-benefit-of-incobotulinum-toxin-a-for-spasticity-of-the-triceps-surae-in-patients-with-multiple-sclerosis-106495https://curecurrent.com/trials/a-pilot-study-in-participants-with-relapsing-remitting-multiple-sclerosis-rr-ms-106496https://curecurrent.com/trials/medical-marijuana-and-its-effects-on-motor-function-in-people-with-multiple-sclerosis-106497https://curecurrent.com/trials/upper-airway-function-and-cardiorespiratory-performance-in-impair-trunk-motor-control-multiple-sclerosis-patients-106498https://curecurrent.com/trials/effects-of-low-intensity-interval-walking-with-blood-flow-restriction-on-functional-capacity-in-multiple-sclerosis-106499https://curecurrent.com/trials/loveyourbrain-yoga-for-multiple-sclerosis-106500https://curecurrent.com/trials/ampyra-for-optic-neuritis-in-multiple-sclerosis-106501https://curecurrent.com/trials/to-study-the-pathophysiological-features-of-multiple-sclerosis-106502https://curecurrent.com/trials/influence-of-socio-economic-factor-on-net-survival-in-patients-with-multiple-sclerosis-in-france-ecovimus-106503https://curecurrent.com/trials/postoperative-relapses-in-ms-patients-106504https://curecurrent.com/trials/drugs-for-the-treatment-of-multiple-sclerosis-and-risk-of-cancer-a-pharmacovigilance-analysis-in-vigibase-106505https://curecurrent.com/trials/treating-anorectal-dysfunction-in-ms-106506https://curecurrent.com/trials/autologous-mesenchymal-stromal-cells-for-multiple-sclerosis-106507https://curecurrent.com/trials/study-to-compare-gi-tolerability-following-oral-administration-of-bafiertam-or-tecfidera-to-healthy-volunteers-106508https://curecurrent.com/trials/high-dose-chemo-radiotherapy-and-hematopoietic-stem-cell-transplant-for-patients-with-multiple-sclerosis-106509https://curecurrent.com/trials/adherence-in-pediatric-multiple-sclerosis-106510https://curecurrent.com/trials/electric-stimulation-of-the-eye-to-improve-vision-after-trauma-106511https://curecurrent.com/trials/safety-tolerability-efficacy-and-optimal-dose-finding-study-of-baf312-in-patients-with-relapsing-remitting-multiple-scle-106512https://curecurrent.com/trials/cognitive-dysfunction-in-ms-using-altered-brain-oscillation-to-link-molecular-mechanisms-with-clinical-outcomes-106513https://curecurrent.com/trials/association-between-fatigue-and-balance-in-patients-with-multiple-sclerosis-106514https://curecurrent.com/trials/exploration-of-brain-changes-due-to-a-targeted-ballet-program-in-multiple-sclerosis-106515https://curecurrent.com/trials/correlation-of-serum-lactate-and-activity-of-multiple-sclerosis-106516https://curecurrent.com/trials/views-on-physical-activity-following-a-relapse-in-people-with-multiple-sclerosis-106517https://curecurrent.com/trials/biomarkers-in-multiple-sclerosis-106518https://curecurrent.com/trials/studies-of-autistic-patients-gene-networks-and-clinical-subtypes-106519https://curecurrent.com/trials/immunologic-biomarker-profile-of-cerebrospinal-fluid-106520https://curecurrent.com/trials/oral-guanabenz-for-multiple-sclerosis-106521https://curecurrent.com/trials/brain-peripheral-benzodiazepine-receptors-in-patients-with-multiple-sclerosis-106522https://curecurrent.com/trials/investigation-of-simvastatin-in-secondary-progressive-multiple-sclerosis-106523https://curecurrent.com/trials/observational-registry-of-acthar-gel-for-participants-with-multiple-sclerosis-relapse-106524https://curecurrent.com/trials/in-clinic-physical-activity-in-persons-with-multiple-sclerosis-106525https://curecurrent.com/trials/long-term-extension-study-in-participants-with-multiple-sclerosis-who-have-completed-study-205ms301-nct01064401-to-evalu-106526https://curecurrent.com/trials/fecal-microbial-transplantation-in-relapsing-multiple-sclerosis-patients-106527https://curecurrent.com/trials/treatment-of-optic-neuritis-with-erythropoietin-a-randomised-double-blind-placebo-controlled-trial-106528https://curecurrent.com/trials/impact-of-acute-leg-cycling-at-various-intensities-on-rls-severity-in-persons-with-ms-106529https://curecurrent.com/trials/effect-of-need-to-void-on-rectal-sensory-function-in-multiple-sclerosis-106530https://curecurrent.com/trials/role-of-simvastatin-in-relapsing-remitting-multiple-sclerosis-106531https://curecurrent.com/trials/a-study-for-testing-text-messaging-and-newsletter-as-a-strategy-for-interrupting-sedentary-behavior-106532https://curecurrent.com/trials/a-study-of-alks-8700-a-monomethyl-fumarate-mmf-molecule-in-healthy-adults-106533https://curecurrent.com/trials/extension-study-of-bg00012-in-pediatric-subjects-with-relapsing-remitting-multiple-sclerosis-rrms-106534https://curecurrent.com/trials/testosterone-treatment-for-multiple-sclerosis-106535https://curecurrent.com/trials/sleep-physical-activity-and-multiple-sclerosis-symptoms-in-pediatric-multiple-sclerosis-106536https://curecurrent.com/trials/prospective-observational-long-term-safety-registry-of-multiple-sclerosis-participants-who-have-participated-in-cladribi-106537https://curecurrent.com/trials/high-intensity-interval-training-for-people-with-mild-multiple-sclerosis-a-feasibility-study-106538https://curecurrent.com/trials/cognitive-motor-interference-in-persons-with-ms-106539https://curecurrent.com/trials/high-intensity-training-and-its-effects-on-neuroplasticity-106540https://curecurrent.com/trials/oct-and-early-cognitive-impairment-in-multiple-sclerosis-106541https://curecurrent.com/trials/sexual-dysfunction-in-patients-with-relapsing-remitting-multiple-sclerosis-and-associated-comorbidities-106542https://curecurrent.com/trials/a-study-with-ipx056-in-subjects-with-spasticity-associated-with-multiple-sclerosis-106543https://curecurrent.com/trials/ipx056-in-subjects-with-established-spasticity-resulting-from-multiple-sclerosis-106544https://curecurrent.com/trials/estriol-treatment-in-multiple-sclerosis-ms-effect-on-cognition-106545https://curecurrent.com/trials/testosterone-for-fatigue-in-men-with-ms-106546https://curecurrent.com/trials/investigating-mechanism-of-action-of-dac-hyp-in-the-treatment-of-high-inflammatory-multiple-sclerosis-ms-106547https://curecurrent.com/trials/impact-of-ketone-bodies-and-epigallocatechin-gallate-in-multiple-sclerosis-106548https://curecurrent.com/trials/fingolimod-versus-dimethyl-fumarate-in-multiple-sclerosis-106549https://curecurrent.com/trials/telephone-delivered-exercise-for-multiple-sclerosis-fatigue-106550https://curecurrent.com/trials/supervised-perturbation-training-results-in-changes-in-balance-and-falling-in-patients-with-multiple-sclerosis-106551https://curecurrent.com/trials/combined-exercise-training-in-patients-with-multiple-sclerosis-106552https://curecurrent.com/trials/observational-study-on-multiple-sclerosis-106553https://curecurrent.com/trials/an-observational-study-on-intermittent-self-catheterisation-discontinuation-factors-in-multiple-sclerosis-patients-106554https://curecurrent.com/trials/atomic-active-teens-with-multiple-sclerosis-teens-a-feasibility-study-106555https://curecurrent.com/trials/trial-of-memantine-for-cognitive-impairment-in-multiple-sclerosis-106556https://curecurrent.com/trials/lakeshore-examination-of-activity-and-disability-exercise-response-study-106557https://curecurrent.com/trials/exercise-on-multiple-sclerosis-patients-106558https://curecurrent.com/trials/to-investigate-the-effect-of-aerobic-exercise-on-neurophysiological-values-and-functionality-in-individuals-with-multipl-106559https://curecurrent.com/trials/scan-rescan-sub-study-of-ms-paths-106560https://curecurrent.com/trials/an-eight-week-rct-of-home-based-pilates-for-symptoms-of-anxiety-depression-and-fatigue-among-people-with-ms-106561https://curecurrent.com/trials/safety-and-tolerability-of-quetiapine-in-multiple-sclerosis-106562https://curecurrent.com/trials/telehealth-based-exercise-program-to-treat-fatigue-in-ms-106563https://curecurrent.com/trials/pilot-trial-of-domperidone-in-relapsing-remitting-multiple-sclerosis-rrms-106564https://curecurrent.com/trials/detection-of-pattern-of-some-unusual-signs-and-symptoms-of-multiple-sclerosis-106565https://curecurrent.com/trials/correlation-between-daily-physical-activity-and-disability-fatigue-cognition-and-quality-of-life-in-ms-patients-106566https://curecurrent.com/trials/intrathecal-rituximab-in-progressive-multiple-sclerosis-106567https://curecurrent.com/trials/correlation-between-pet-and-advanced-mri-in-multiple-sclerosis-106568https://curecurrent.com/trials/xo-as-a-screening-test-of-cognitive-impairment-in-multiple-sclerosis-106569https://curecurrent.com/trials/relationship-between-the-nutritional-habits-and-relapsing-and-disability-rates-in-patient-with-multiple-sclerosis-106570https://curecurrent.com/trials/effects-of-functional-electrical-stimulation-cycling-versus-cycling-only-on-walking-and-quality-of-life-in-ms-106571https://curecurrent.com/trials/fingolimod-effect-on-cytokine-and-chemokine-levels-106572https://curecurrent.com/trials/efficacy-and-safety-of-daclizumab-in-participants-with-rrms-switching-from-natalizumab-106573https://curecurrent.com/trials/home-exercise-intervention-in-persons-with-multiple-sclerosis-106574https://curecurrent.com/trials/a-post-authorization-safety-study-of-interferon-beta-therapy-in-participants-with-multiple-sclerosis-106575https://curecurrent.com/trials/study-to-validate-telemetric-ecg-systems-for-first-dose-administration-of-fingolimod-start-106576https://curecurrent.com/trials/signatures-of-immune-reprogramming-in-anti-cd52-therapy-of-ms-markers-for-risk-stratification-and-treatment-response-106577https://curecurrent.com/trials/study-of-biomarkers-of-the-response-to-biotine-106578https://curecurrent.com/trials/measurement-and-training-of-dual-task-of-gait-in-persons-with-multiple-sclerosis-106579https://curecurrent.com/trials/comparison-of-two-community-based-exercise-protocols-in-people-with-multiple-sclerosis-106580https://curecurrent.com/trials/comparison-of-the-efficacy-and-mechanisms-for-mbct-and-ct-for-multiple-sclerosis-ms-chronic-pain-106581https://curecurrent.com/trials/efficacy-and-safety-of-4-aminopyridine-on-cognitive-performance-and-motor-function-of-patients-with-multiple-sclerosis-106582https://curecurrent.com/trials/immunoadsorption-vs-plasmapheresis-in-the-escalation-therapy-of-relapse-in-multiple-sclerosis-106583https://curecurrent.com/trials/a-pilot-study-of-lithium-in-progressive-multiple-sclerosis-106584https://curecurrent.com/trials/acth-for-fatigue-in-multiple-sclerosis-patients-106585https://curecurrent.com/trials/effect-of-transorbital-electrical-stimulation-of-optic-nerve-on-remyelination-after-an-acute-optic-neuritis-106586https://curecurrent.com/trials/feasibility-of-web-based-cbt-i-intervention-in-individuals-with-multiple-sclerosis-106587https://curecurrent.com/trials/the-effect-of-aerobic-exercise-on-cognitive-function-and-sleep-quality-in-individuals-with-multiple-sclerosis-106588https://curecurrent.com/trials/vigorous-cool-room-treadmill-training-106589https://curecurrent.com/trials/cognitive-behavioral-therapy-for-insomnia-to-address-insomnia-symptoms-in-people-with-multiple-sclerosis-106590https://curecurrent.com/trials/transcranial-magnetic-stimulation-tms-in-multiple-sclerosis-106591https://curecurrent.com/trials/evaluating-the-use-of-prednisone-to-decrease-pegylated-interferon-beta-1a-side-effects-106592https://curecurrent.com/trials/effects-of-a-weight-based-training-program-on-ms-patients-106593https://curecurrent.com/trials/epid-multiple-sclerosis-pregnancy-study-106594https://curecurrent.com/trials/open-label-study-to-evaluate-the-efficacy-of-ecp-in-secondary-progressive-multiple-sclerosis-106595https://curecurrent.com/trials/attention-working-memory-rehabilitation-in-multiple-sclerosis-a-pilot-project-using-cogmed-working-memory-training-106596https://curecurrent.com/trials/evaluation-of-a-modified-paleolithic-dietary-intervention-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-106597https://curecurrent.com/trials/real-world-data-of-ocrelizumab-in-multiple-sclerosis-in-latam-106598https://curecurrent.com/trials/multiple-sclerosis-registry-in-argentina-relevarem-106599https://curecurrent.com/trials/respiratory-functions-trunk-control-and-mobility-evaluation-in-multiple-sclerosis-106600https://curecurrent.com/trials/from-clinic-to-community-an-information-and-communication-technology-ict-home-based-exercise-training-system-for-transla-106601https://curecurrent.com/trials/clinical-efficacy-of-autologous-mesenchymal-bone-marrow-stem-cells-in-active-progressive-multiple-sclerosis-106602https://curecurrent.com/trials/dual-task-performance-in-patients-with-multiple-sclerosis-106603https://curecurrent.com/trials/the-effect-of-multiple-task-training-in-patients-with-multiple-sclerosis-106604https://curecurrent.com/trials/effectiveness-of-a-schema-therapy-on-anxiety-in-patients-with-multiple-sclerosis-106605https://curecurrent.com/trials/decision-making-in-multiple-sclerosis-care-under-uncertainty-106606https://curecurrent.com/trials/lee-silverman-voice-treatment-versus-standard-speech-therapy-versus-control-in-hypophonia-rehabilitation-in-ms-106607https://curecurrent.com/trials/the-role-of-sativex-in-robotic-rehabilitation-106608https://curecurrent.com/trials/isokinetic-exercises-in-patients-with-multiple-sclerosis-106609https://curecurrent.com/trials/integrating-caregiver-support-into-ms-care-106610https://curecurrent.com/trials/virtual-reality-for-upper-limb-rehabilitation-in-multiple-sclerosis-106611https://curecurrent.com/trials/pilot-test-of-actos-in-multiple-sclerosis-safety-and-tolerability-106612https://curecurrent.com/trials/effect-of-need-to-void-on-gait-speed-in-multiple-sclerosis-106613https://curecurrent.com/trials/incidence-and-survival-medical-expenditure-of-patients-with-multiple-sclerosis-106614https://curecurrent.com/trials/towards-personalized-dosing-of-natalizumab-in-multiple-sclerosis-106615https://curecurrent.com/trials/guided-versus-non-guided-pelvic-floor-exercises-for-urinary-incontinence-in-relapsing-remitting-multiple-sclerosis-106616https://curecurrent.com/trials/thermal-cures-in-the-treatment-of-multiple-sclerosis-106617https://curecurrent.com/trials/exploring-the-use-of-non-invasive-neuromodulation-combined-with-exercise-in-people-with-advanced-multiple-sclerosis-ms-106618https://curecurrent.com/trials/interoception-and-sense-of-movement-in-the-patient-with-multiple-sclerosis-106619https://curecurrent.com/trials/unraveling-early-walking-dysfunction-in-non-disabled-ms-people-assessment-and-potential-therapeutic-interventions-106620https://curecurrent.com/trials/bosentan-treatment-of-digital-ulcers-related-to-systemic-sclerosis-106621https://curecurrent.com/trials/e-reporting-of-adverse-drug-reactions-by-patients-in-relapsing-remitting-multiple-sclerosis-106622https://curecurrent.com/trials/effect-of-bg00012-on-lymphocyte-subsets-and-immunoglobulins-in-subjects-with-relapsing-remitting-multiple-sclerosis-rrms-106623https://curecurrent.com/trials/exercise-brain-health-in-ms-106624https://curecurrent.com/trials/an-observational-study-to-collect-information-on-safety-and-to-document-the-drug-utilization-of-fampyra-biib041-when-use-106625https://curecurrent.com/trials/obstetric-anesthesia-and-analgesia-and-multiple-sclerosis-106626https://curecurrent.com/trials/wearable-lower-extremity-exoskeleton-to-promote-walking-in-persons-with-multiple-sclerosis-106627https://curecurrent.com/trials/ms-study-evaluating-safety-and-efficacy-of-two-doses-of-fingolimod-versus-copaxone-106628https://curecurrent.com/trials/comparison-of-clinical-effects-of-rituximab-and-glatiramer-acetate-in-secondary-progressive-multiple-sclerosis-patients-106629https://curecurrent.com/trials/vojta-therapy-in-multiple-sclerosis-106630https://curecurrent.com/trials/benefit-15-long-term-follow-up-study-of-the-benefit-and-benefit-follow-up-studies-106631https://curecurrent.com/trials/evaluating-of-the-effect-of-fingolimod-with-fish-oil-on-relapsing-remitting-multiple-sclerosis-patients-106632https://curecurrent.com/trials/riluzole-oral-soluble-film-safety-and-tolerability-in-amyotrophic-lateral-sclerosis-106633https://curecurrent.com/trials/innovative-physiotherapy-and-coordination-of-care-for-people-with-ms-a-rct-and-a-qualitative-study-106634https://curecurrent.com/trials/balance-trunk-impairment-and-fear-of-falling-in-multiple-sclerosis-patients-with-incontinence-106635https://curecurrent.com/trials/magnetic-resonance-imaging-study-of-jm-4-in-multiple-sclerosis-clinically-patients-106636https://curecurrent.com/trials/a-study-to-evaluate-the-effects-of-multiple-doses-of-ck-2017357-in-patients-with-amyotrophic-lateral-sclerosis-als-106637https://curecurrent.com/trials/task-oriented-upper-limb-training-in-ms-106638https://curecurrent.com/trials/study-of-sparc1103-in-subjects-with-spasticity-106639https://curecurrent.com/trials/effects-of-inspiratory-muscle-training-in-persons-with-advanced-multiple-sclerosis-106640https://curecurrent.com/trials/a-long-term-follow-up-study-of-botulinum-toxin-type-a-in-patients-with-overactive-bladder-as-a-result-of-spinal-injury-o-106641https://curecurrent.com/trials/escitalopram-lexapro-for-depression-ms-or-als-106642https://curecurrent.com/trials/keratinocyte-growth-factor-to-prevent-autoimmunity-after-alemtuzumab-treatment-of-multiple-sclerosis-106643https://curecurrent.com/trials/safety-and-efficacy-study-of-onabotulinumtoxina-for-the-treatment-of-urinary-incontinence-due-to-neurogenic-detrusor-ove-106644https://curecurrent.com/trials/reliability-and-validity-of-the-turkish-version-of-the-multiple-sclerosis-knowledge-questionnaire-106645https://curecurrent.com/trials/rouxbe-pilot-for-ms-106646https://curecurrent.com/trials/assesment-of-physical-activity-level-of-patients-with-multiple-sclerosis-from-laboratory-to-real-life-106647https://curecurrent.com/trials/lipoic-acid-as-a-treatment-for-acute-optic-neuritis-106648https://curecurrent.com/trials/validation-of-a-laboratory-test-measuring-natalizumab-tysabri-serum-levels-in-ms-106649https://curecurrent.com/trials/pet-study-in-multiple-sclerosis-106650https://curecurrent.com/trials/video-game-based-therapy-for-arm-weakness-in-progressive-multiple-sclerosis-106651https://curecurrent.com/trials/correlation-between-the-nine-holes-peg-test-performance-and-the-triple-stimulation-technique-within-a-group-a-patients-w-106652https://curecurrent.com/trials/effects-of-gilenya-fingolimod-on-thalamus-pathology-and-cognitive-impairment-in-patients-with-relapsing-forms-of-multipl-106653https://curecurrent.com/trials/use-of-the-nine-holes-peg-test-in-multiple-sclerosis-participation-of-elementary-neurological-components-in-the-function-106654https://curecurrent.com/trials/does-long-term-natalizumab-ntz-therapy-normalize-brain-atrophy-rates-and-quality-of-life-qol-in-relapsing-remitting-mult-106655https://curecurrent.com/trials/impact-of-exercise-on-invisible-symptoms-and-quality-of-life-in-multiple-sclerosis-individuals-106656https://curecurrent.com/trials/validation-of-a-smartwatch-in-persons-with-multiple-sclerosis-106657https://curecurrent.com/trials/biofeedback-based-relaxation-training-or-self-alert-training-to-alleviate-fatigue-in-multiple-sclerosis-patients-106658https://curecurrent.com/trials/potential-eeg-biomarkers-and-antiepileptogenic-strategies-for-epilepsy-in-tsc-106659https://curecurrent.com/trials/resilience-based-program-for-support-partners-of-persons-with-multiple-sclerosis-106660https://curecurrent.com/trials/fall-prevention-program-for-non-ambulatory-wheeled-mobility-device-users-living-with-ms-106661https://curecurrent.com/trials/profile-evaluation-of-qol-and-pro-outcomes-in-patients-taking-fingolimod-106662https://curecurrent.com/trials/an-extension-study-of-laq-5062-exploring-the-long-term-safety-tolerability-and-clinical-effect-parameters-during-the-dis-106663https://curecurrent.com/trials/medication-usage-and-patient-reported-outcomes-evaluation-via-mybetaapp-in-patients-with-multiple-sclerosis-treated-with-106664https://curecurrent.com/trials/inspiratory-muscle-training-in-multiple-sclerosis-106665https://curecurrent.com/trials/comparing-tolerability-and-absorption-of-racemic-and-r-lipoic-acid-in-progressive-multiple-sclerosis-106666https://curecurrent.com/trials/multidimensional-assessment-of-fatigue-in-multiple-sclerosis-observational-study-ticino-106667https://curecurrent.com/trials/impact-of-vitamin-d-supplementation-in-patients-with-multiple-sclerosis-106668https://curecurrent.com/trials/clinical-trial-of-idebenone-in-primary-progressive-multiple-sclerosis-ippoms-106669https://curecurrent.com/trials/supraspinal-control-of-lower-urinary-tract-function-in-healthy-controls-and-patients-with-bladder-dysfunction-106670https://curecurrent.com/trials/follow-up-of-persons-with-multiple-sclerosis-106671https://curecurrent.com/trials/feasibility-and-reliability-of-multimodal-evoked-potentials-in-an-international-multicenter-setting-106672https://curecurrent.com/trials/cognitive-evolution-in-tysabri-treated-multiple-sclerosis-patients-106673https://curecurrent.com/trials/effect-of-fasting-on-the-size-of-abdominal-lymphatic-tumors-in-women-106674https://curecurrent.com/trials/prolonged-release-fampridine-as-adjunct-therapy-to-active-motor-training-in-ms-patients-106675https://curecurrent.com/trials/pharmacokinetics-of-vitamin-d-in-multiple-sclerosis-and-in-health-106676https://curecurrent.com/trials/assessment-of-walking-related-fatigability-in-patients-with-multiple-sclerosis-106677https://curecurrent.com/trials/online-spaced-education-to-improve-fall-prevention-by-patients-with-multiple-sclerosis-106678https://curecurrent.com/trials/standardized-ambulatory-neurorehabilitation-program-for-patients-with-multiple-sclerosis-106679https://curecurrent.com/trials/mindfulness-based-stress-reduction-in-multiple-sclerosis-106680https://curecurrent.com/trials/acute-effects-of-whole-body-vibration-training-in-hypoxia-and-normoxia-in-multiple-sclerosis-patients-106681https://curecurrent.com/trials/effect-of-fingolimod-on-neurodegeneration-106682https://curecurrent.com/trials/monitoring-of-multiple-sclerosis-ms-participants-with-the-use-of-digital-technology-smartphones-and-smartwatches-a-feasi-106683https://curecurrent.com/trials/mitochondrial-dysfunction-and-disease-progression-106684https://curecurrent.com/trials/long-term-trial-of-topical-sirolimus-to-angiofibroma-in-patient-with-tuberous-sclerosis-complex-106685https://curecurrent.com/trials/upper-extremity-function-shoulder-position-sense-and-disability-level-i-n-patients-with-multiple-sclerosis-106686https://curecurrent.com/trials/how-does-strength-training-and-balance-training-affect-gait-function-and-fatigue-in-patients-with-multiple-sclerosis-106687https://curecurrent.com/trials/fampridine-in-ms-patients-a-cognition-fatigue-depression-and-quality-of-life-analysis-106688https://curecurrent.com/trials/observational-study-of-tysabri-in-early-relapsing-remitting-multiple-sclerosis-in-anti-jc-virus-antibody-negative-partic-106689https://curecurrent.com/trials/follow-up-study-of-patients-on-fingolimod-who-were-enrolled-in-the-original-biobank-study-cfty720dde01-106690https://curecurrent.com/trials/helminth-induced-immunomodulation-therapy-hint-in-relapsing-remitting-multiple-sclerosis-106691https://curecurrent.com/trials/urodynamic-and-clinical-efficacy-of-mirabegron-for-neurogenic-bladder-patients-106692https://curecurrent.com/trials/cognitive-functions-in-patients-with-multiple-sclerosis-106693https://curecurrent.com/trials/study-to-evaluate-the-reliability-and-validity-of-the-modified-manual-muscle-test-for-persons-with-ms-106694https://curecurrent.com/trials/the-effect-of-task-oriented-training-in-patients-with-multiple-sclerosis-106695https://curecurrent.com/trials/vestibular-rehabilitation-for-persons-with-multiple-sclerosis-who-benefits-the-most-msvr3trial-106696https://curecurrent.com/trials/central-pain-study-for-abx-1431-106697https://curecurrent.com/trials/efficacy-of-fingolimod-in-de-novo-patients-versus-fingolimod-in-patients-previously-treated-with-a-first-line-disease-mo-106698https://curecurrent.com/trials/assessing-fatiguability-of-tongue-muscles-in-ms-106699https://curecurrent.com/trials/feasibility-and-reliability-of-multimodal-evoked-potentials-106700https://curecurrent.com/trials/dietary-supplement-of-curcumin-in-subjects-with-active-relapsing-multiple-sclerosis-treated-with-subcutaneous-interferon-106701https://curecurrent.com/trials/measuring-satisfaction-of-treatment-with-rebif-after-initial-treatment-of-multiple-sclerosis-ms-106702https://curecurrent.com/trials/effects-of-aerobic-and-isokinetic-exercise-in-multiple-sclerosis-106703https://curecurrent.com/trials/sleep-apnea-in-multiple-sclerosis-positive-airway-pressure-trial-106704https://curecurrent.com/trials/monitoring-of-patients-followed-for-a-multiple-sclerosis-and-treated-by-dimethyl-fumarate-106705https://curecurrent.com/trials/effects-of-fingolimod-on-heart-rhythm-and-heart-rate-variability-in-patients-with-multiple-sclerosis-106706https://curecurrent.com/trials/alexithymia-frequency-and-interhemispheric-transfer-in-patients-with-a-first-demyelinating-event-106707https://curecurrent.com/trials/clinical-disease-activity-with-long-term-natalizumab-treatment-106708https://curecurrent.com/trials/the-impact-of-exercise-training-on-living-quality-in-multiple-sclerosis-individuals-106709https://curecurrent.com/trials/teriflunomide-male-transmission-study-106710https://curecurrent.com/trials/implementation-intention-for-physical-activity-in-multiple-sclerosis-106711https://curecurrent.com/trials/interferon-ss-1b-treatment-by-cyclical-administration-106712https://curecurrent.com/trials/betaseron-pregnancy-registry-106713https://curecurrent.com/trials/feasability-validty-and-reliability-of-inertial-sensors-106714https://curecurrent.com/trials/masitinib-in-primary-progressive-multiple-sclerosis-or-relapse-free-secondary-progressive-multiple-sclerosis-106715https://curecurrent.com/trials/alemtuzumab-on-surrogate-markers-of-disease-activity-and-repair-using-advanced-mri-measures-in-subjects-with-relapsing-r-106716https://curecurrent.com/trials/changes-in-physical-activity-in-all-day-life-in-people-with-ms-before-and-after-rehabilitation-106717https://curecurrent.com/trials/mesenchymal-stem-cells-for-multiple-sclerosis-106718https://curecurrent.com/trials/a-task-oriented-circuit-training-in-multiple-sclerosis-106719https://curecurrent.com/trials/aerobic-exercise-and-transcranial-low-laser-therapy-in-patients-with-central-nervous-system-injury-106720https://curecurrent.com/trials/study-to-investigate-the-immune-response-and-safety-of-prophylactic-vaccines-in-patients-treated-for-multiple-sclerosis-106721https://curecurrent.com/trials/impact-of-brain-connectome-and-personality-on-cognitive-rehabilitation-in-multiple-sclerosis-106722https://curecurrent.com/trials/fatigue-and-inspiratory-muscles-training-in-patients-with-multiple-sclerosis-106723https://curecurrent.com/trials/the-reliability-validity-and-responsiveness-of-the-timed-360-turn-test-in-patients-with-multiple-sclerosis-106724https://curecurrent.com/trials/tmp001-in-relapsing-remitting-multiple-sclerosis-106725https://curecurrent.com/trials/an-efficacy-and-safety-study-of-bg00012-dimethyl-fumarate-in-asian-subjects-with-relapsing-remitting-multiple-sclerosis-106726https://curecurrent.com/trials/aspirin-as-a-pre-treatment-for-exercise-in-multiple-sclerosis-106727https://curecurrent.com/trials/thyroid-hormone-for-remyelination-in-multiple-sclerosis-ms-a-safety-and-dose-finding-study-106728https://curecurrent.com/trials/a-study-of-participants-with-relapsing-remitting-multiple-sclerosis-rrms-106729https://curecurrent.com/trials/biologic-basis-for-multiple-sclerosis-disease-progression-in-rrms-patients-treated-with-gilenya-106730https://curecurrent.com/trials/safety-and-efficacy-extension-study-of-daclizumab-high-yield-process-dac-hyp-biib019-in-participants-who-have-completed-106731https://curecurrent.com/trials/effects-of-tysabri-bg00002-over-12-months-on-ms-related-fatigue-in-participants-with-rrms-106732https://curecurrent.com/trials/exercise-based-therapy-for-multiple-sclerosis-patients-106733https://curecurrent.com/trials/multi-joint-muscle-fatigability-and-gait-performance-in-people-with-multiple-sclerosis-106734https://curecurrent.com/trials/clinical-importance-of-glucose-regulation-in-relapsing-ms-106735https://curecurrent.com/trials/long-term-effects-of-torso-weighting-106736https://curecurrent.com/trials/a-placebo-controlled-trial-of-dalfampridine-er-for-ambulatory-activity-in-people-with-multiple-sclerosis-106737https://curecurrent.com/trials/physiology-of-interregional-connectivity-in-the-human-brain-106738https://curecurrent.com/trials/safety-and-tolerability-study-of-medi-551-a-b-cell-depleting-agent-to-treat-relapsing-forms-of-multiple-sclerosis-106739https://curecurrent.com/trials/effects-of-exercises-in-ms-on-postural-control-with-dual-task-106740https://curecurrent.com/trials/a-trial-to-compare-the-effectiveness-of-two-rehabilitation-programs-for-multiple-sclerosis-patients-106741https://curecurrent.com/trials/neurodynamic-interventions-for-multiple-sclerosis-106742https://curecurrent.com/trials/vision-assessment-with-the-quick-contrast-sensitivity-function-qcsf-method-in-healthy-controls-and-ms-106743https://curecurrent.com/trials/evaluate-safety-and-efficacy-of-apitox-add-on-therapy-for-improving-disability-and-quality-of-life-in-ms-patients-106744https://curecurrent.com/trials/characterization-of-interferon-beta-1b-induced-tolerizing-effect-in-dendritic-cells-106745https://curecurrent.com/trials/environmental-and-genetic-risk-factors-for-pediatric-multiple-sclerosis-106746https://curecurrent.com/trials/power-over-pain-pop-study-106747https://curecurrent.com/trials/characterizing-sleep-disorders-in-children-and-adults-with-tuberous-sclerosis-complex-tsc-106748https://curecurrent.com/trials/advanced-mri-measures-of-repair-in-alemtuzumab-treated-patients-106749https://curecurrent.com/trials/effects-of-immersive-virtual-reality-on-balance-mobility-and-fatigue-in-patients-with-multiple-sclerosis-106750https://curecurrent.com/trials/baseline-cortical-haemodynamics-in-ms-106751https://curecurrent.com/trials/effect-of-photobiomodulation-treatment-in-individuals-with-multiple-sclerosis-106752https://curecurrent.com/trials/investigation-of-the-effect-of-dimethyl-fumarate-on-t-cells-in-patients-with-relapsing-remitting-multiple-sclerosis-106753https://curecurrent.com/trials/effects-of-training-on-central-auditory-function-in-multiple-sclerosis-106754https://curecurrent.com/trials/prospective-longitudinal-1-year-study-of-the-correlation-between-cognitive-functioning-in-patients-with-clinically-isola-106755https://curecurrent.com/trials/pilot-diet-study-for-multiple-sclerosis-106756https://curecurrent.com/trials/influence-of-cognitive-function-software-therapy-on-the-improvement-of-manual-skills-in-multiple-sclerosis-patients-106757https://curecurrent.com/trials/high-dose-cyclophosphamide-followed-by-glatiramer-acetate-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-106758https://curecurrent.com/trials/effects-aquatic-exercises-on-balance-and-hand-function-in-multiple-sclerosis-106759https://curecurrent.com/trials/a-study-of-rebif-in-subjects-with-relapsing-multiple-sclerosis-106760https://curecurrent.com/trials/the-immunomodulatory-effects-of-oral-nanocurcumin-in-multiple-sclerosis-patients-106761https://curecurrent.com/trials/digitalization-of-neurofunctional-tests-via-a-mobile-application-dams-for-multiple-sclerosis-patients-106762https://curecurrent.com/trials/reliability-validity-and-clinical-utility-of-a-robotic-assessment-for-proprioception-106763https://curecurrent.com/trials/forty-five-patients-with-multiple-sclerosis-recieved-vestibular-rehabilitation-and-balance-training-106764https://curecurrent.com/trials/observational-study-to-assess-the-correlation-of-edss-with-quality-of-life-in-ms-participants-treated-with-natalizumab-106765https://curecurrent.com/trials/study-of-oral-fampridine-sr-in-multiple-sclerosis-106766https://curecurrent.com/trials/urinary-markers-of-detrusor-overactivity-in-spina-bifida-patients-106767https://curecurrent.com/trials/high-field-mri-iron-based-contrast-enhanced-characterization-of-multiple-sclerosis-and-demyelinating-diseases-106768https://curecurrent.com/trials/efficacy-of-mbi-for-depressive-symptoms-in-patients-with-ms-106769https://curecurrent.com/trials/study-evaluating-rapid-infusion-rituximab-in-patients-with-autoimmune-diseases-106770https://curecurrent.com/trials/urinary-disorders-in-patients-with-multiple-sclerosis-invasive-vs-non-invasive-investigations-106771https://curecurrent.com/trials/impact-of-the-betaconnect-auto-injector-on-betaseron-therapy-adherence-and-patient-satisfaction-106772https://curecurrent.com/trials/outcomes-data-of-adipose-stem-cells-to-treat-multiple-sclerosis-106773https://curecurrent.com/trials/validation-of-a-self-questionnaire-in-french-on-the-use-of-the-upper-limbs-in-patients-with-multiple-sclerosis-106774https://curecurrent.com/trials/tecfidera-and-mri-for-brain-energy-in-ms-106775https://curecurrent.com/trials/the-sems-project-staying-employed-with-ms-106776https://curecurrent.com/trials/resistance-training-and-amino-pyridine-in-multiple-sclerosis-106777https://curecurrent.com/trials/repeat-infusion-of-autologous-bone-marrow-cells-in-multiple-sclerosis-106778https://curecurrent.com/trials/fame-fampyra-outcome-measures-study-a-study-of-different-outcome-measures-on-the-effect-of-fampyra-106779https://curecurrent.com/trials/benefits-evaluation-of-selfia-adapted-underwear-for-ms-patients-performing-self-catheterization-106780https://curecurrent.com/trials/an-intravenous-infusion-study-of-rhigm22-in-patients-with-multiple-sclerosis-immediately-following-a-relapse-106781https://curecurrent.com/trials/assessing-induction-of-type-ii-m2-monocytes-macrophages-in-patients-receiving-gilenya-106782https://curecurrent.com/trials/evaluation-of-nutritional-status-and-fatigue-in-patients-with-multiple-sclerosis-106783https://curecurrent.com/trials/depicting-neurogenic-dysphagia-in-multiple-sclerosis-patients-clinical-and-endoscopic-studies-106784https://curecurrent.com/trials/characterization-of-cortical-injury-in-early-ms-patients-a-7t-mri-study-106785https://curecurrent.com/trials/retrospective-study-to-determine-effect-of-rebif-and-tecfidera-on-infections-and-lymphocytes-106786https://curecurrent.com/trials/effect-of-motor-entrainment-to-auditory-cues-and-music-during-walking-on-quality-of-movement-and-perceived-fatigue-in-pe-106787https://curecurrent.com/trials/adaptive-plasticity-following-rehabilitation-in-multiple-sclerosis-106788https://curecurrent.com/trials/advanced-mri-sequences-in-multiple-sclerosis-and-its-mimics-106789https://curecurrent.com/trials/a-randomized-trial-of-two-formal-group-programs-for-multiple-sclerosis-106790https://curecurrent.com/trials/characterization-of-white-blood-cells-sub-populations-from-multiple-sclerosis-patients-106791https://curecurrent.com/trials/the-effects-of-different-medical-marijuana-strains-on-motor-and-cognitive-function-in-people-with-multiple-sclerosis-106792https://curecurrent.com/trials/a-cognitive-self-management-intervention-for-persons-with-multiple-sclerosis-adapting-web-based-technology-106793https://curecurrent.com/trials/the-reliability-validity-and-responsiveness-of-the-static-balance-test-in-patients-with-multiple-sclerosis-106794https://curecurrent.com/trials/treating-ms-patients-with-lower-extremity-spasticity-using-dysport-106795https://curecurrent.com/trials/betaferon-use-in-children-and-adolescents-with-multiple-sclerosis-106796https://curecurrent.com/trials/multiple-sclerosis-and-pilates-106797https://curecurrent.com/trials/assessment-of-bone-marrow-derived-cellular-therapy-in-progressive-multiple-sclerosis-actimus-106798https://curecurrent.com/trials/rebif-versus-copaxone-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-106799https://curecurrent.com/trials/wahls-paleo-diet-and-progressive-multiple-sclerosis-106800https://curecurrent.com/trials/nutrition-neuromuscular-electrical-stimulation-nmes-and-secondary-progressive-multiple-sclerosis-spms-106801https://curecurrent.com/trials/study-of-betaferon-adherence-in-patients-with-multiple-sclerosis-treated-with-interferon-beta-1b-106802https://curecurrent.com/trials/robot-assisted-arm-training-in-multiple-sclerosis-106803https://curecurrent.com/trials/a-pragmatic-trial-of-dietary-programs-in-people-with-multiple-sclerosis-ms-106804https://curecurrent.com/trials/rehabilitation-in-multiple-sclerosis-sometimes-too-much-106805https://curecurrent.com/trials/evaluation-of-the-incidence-of-relapses-in-patients-with-biotin-treated-progressive-multiple-sclerosis-106806https://curecurrent.com/trials/comparison-of-rituximab-induction-therapy-followed-by-glatiramer-acetate-106807https://curecurrent.com/trials/internet-based-motomed-exercise-to-reduce-spasticity-and-improve-physical-function-in-persons-with-multiple-sclerosis-106808https://curecurrent.com/trials/ofatumumab-subcutaneous-administration-in-subjects-with-relapsing-remitting-multiple-sclerosis-106809https://curecurrent.com/trials/implementing-physical-activity-guidelines-for-adults-with-ms-106810https://curecurrent.com/trials/drug-risk-aversion-calculator-use-to-facilitate-ms-patient-self-efficacy-106811https://curecurrent.com/trials/multi-center-study-safety-of-adipose-derived-mesenchymal-stem-cells-for-the-treatment-of-multiple-sclerosis-106812https://curecurrent.com/trials/trial-of-safety-and-efficacy-of-rasagiline-in-patients-with-amyotrophic-lateral-sclerosis-als-106813https://curecurrent.com/trials/cannabis-for-spasticity-in-multiple-sclerosis-106814https://curecurrent.com/trials/amiloride-clinical-trial-in-optic-neuritis-106815https://curecurrent.com/trials/a-multiple-dose-study-of-abt-555-in-subjects-with-relapsing-forms-of-multiple-sclerosis-106816https://curecurrent.com/trials/pf-00489791-for-the-treatment-of-raynaud-s-106817https://curecurrent.com/trials/sphingosine-1-phosphate-receptor-targeting-and-microglial-activation-106818https://curecurrent.com/trials/pathologic-mri-findings-in-atypical-iidd-106819https://curecurrent.com/trials/ireland-natalizumab-tysabri-observational-program-106820https://curecurrent.com/trials/exploratory-study-to-assess-clinical-response-to-gilenya-fingolimod-in-hispanics-with-rrms-106821https://curecurrent.com/trials/turmeric-as-treatment-in-epilepsy-106822https://curecurrent.com/trials/exploration-of-microcirculatory-alteration-and-endothelial-dysfunction-by-adaptive-optics-in-multiple-sclerosis-106823https://curecurrent.com/trials/gene-expression-in-ms-patients-before-and-during-treatment-with-interferon-beta-106824https://curecurrent.com/trials/clinical-pilates-training-for-persons-with-multiple-sclerosis-106825https://curecurrent.com/trials/protective-role-of-oxcarbazepine-in-multiple-sclerosis-106826https://curecurrent.com/trials/cognitive-and-emotion-regulation-training-in-ms-106827https://curecurrent.com/trials/interventional-clinical-trial-for-ccsvi-in-multiple-sclerosis-patients-106828https://curecurrent.com/trials/vaccine-exposure-in-patients-with-ms-106829https://curecurrent.com/trials/strength-training-to-improve-gait-in-people-with-multiple-sclerosis-106830https://curecurrent.com/trials/combination-therapy-with-avonex-and-bimonthly-high-dose-intravenous-methotrexate-in-multiple-sclerosis-106831https://curecurrent.com/trials/using-optical-coherence-tomography-to-capture-retinal-microvascular-changes-associated-with-multiple-sclerosis-106832https://curecurrent.com/trials/progression-of-cognitive-and-physical-symptoms-in-multiple-sclerosis-106833https://curecurrent.com/trials/induction-therapy-with-a-single-high-dose-bolus-of-intravenous-methotrexate-with-leucovorin-rescue-prior-to-initiation-o-106834https://curecurrent.com/trials/anesthetic-topical-adhesive-synera-to-reduce-injection-pain-with-subcutaneous-multiple-sclerosis-medications-106835https://curecurrent.com/trials/evaluation-of-a-web-based-fall-prevention-program-on-people-with-multiple-sclerosis-106836https://curecurrent.com/trials/mindfulness-based-stress-reduction-for-multiple-sclerosis-106837https://curecurrent.com/trials/effects-of-vitamin-k-on-redness-associated-with-injection-site-reactions-in-participants-treated-with-plegridy-106838https://curecurrent.com/trials/methylphenidate-to-improve-balance-and-walking-in-ms-106839https://curecurrent.com/trials/noninterventional-study-assessing-cognitive-function-and-physical-activity-in-people-with-multiple-sclerosis-106840https://curecurrent.com/trials/the-impact-of-positive-mental-training-in-multiple-sclerosis-106841https://curecurrent.com/trials/enhance-wellness-for-individuals-with-long-term-physical-disabilities-106842https://curecurrent.com/trials/motor-imagery-training-in-persons-with-multiple-sclerosis-106843https://curecurrent.com/trials/effectiveness-of-rebif-in-clinically-isolated-syndrome-and-relapsing-multiple-sclerosis-using-rebismart-106844https://curecurrent.com/trials/long-term-safety-tolerability-and-efficacy-of-baf312-given-orally-in-patients-with-relapsing-remitting-multiple-sclerosi-106845https://curecurrent.com/trials/pharmacokinetics-and-pharmacodynamics-study-of-rpc1063-in-rms-106846https://curecurrent.com/trials/investigating-indirect-mechanism-of-neuroprotection-of-tecfidera-dimethyl-fumarate-in-rrms-and-progressive-patients-106847https://curecurrent.com/trials/atorvastatin-in-relapsing-remitting-multiple-sclerosis-106848https://curecurrent.com/trials/flupirtine-as-oral-treatment-in-multiple-sclerosis-106849https://curecurrent.com/trials/intrathecal-administration-of-autologous-mesenchymal-stem-cell-derived-neural-progenitors-msc-np-in-patients-with-multip-106850https://curecurrent.com/trials/evaluation-of-autologous-mesenchymal-stem-cell-transplantation-effects-and-side-effects-in-multiple-sclerosis-106851https://curecurrent.com/trials/study-of-vsn16r-for-the-treatment-of-spasticity-in-multiple-sclerosis-106852https://curecurrent.com/trials/patient-real-world-clinical-neurological-tolerability-and-safety-outcomes-for-tecfidera-and-rebif-106853https://curecurrent.com/trials/reproductibility-of-cystometry-in-multiple-sclerosis-patient-106854https://curecurrent.com/trials/this-is-a-randomized-study-comparing-two-doses-of-int131-3-mg-and-1-mg-administered-orally-po-daily-qd-versus-placebo-1-106855https://curecurrent.com/trials/rebif-advanced-magnetic-resonance-imaging-mri-and-immunology-pilot-trial-106856https://curecurrent.com/trials/effects-of-core-stability-training-on-gait-in-multiple-sclerosis-patients-106857https://curecurrent.com/trials/comparison-of-two-different-virtual-reality-methods-in-patients-with-multiple-sclerosis-106858https://curecurrent.com/trials/investigating-the-relationship-between-sleep-quality-of-life-other-disorders-and-therapies-in-ms-patients-on-betaferon-106859https://curecurrent.com/trials/a-24-hour-pharmacokinetic-determination-of-bg00012-after-single-day-oral-administration-in-subjects-with-ms-106860https://curecurrent.com/trials/effect-of-motor-cortex-versus-sacral-magnetic-stimulation-in-multiple-sclerosis-patients-with-urinary-tract-dysfunction-106861https://curecurrent.com/trials/paris-visual-learning-test-a-new-french-task-for-assess-visual-learning-and-memory-to-multiple-sclerosis-patients-106862https://curecurrent.com/trials/open-label-study-of-liothyronine-in-ms-106863https://curecurrent.com/trials/a-pilot-study-assessing-the-impact-of-gilenya-therapy-on-bone-density-change-in-relapsing-forms-of-multiple-sclerosis-106864https://curecurrent.com/trials/effects-of-vaporized-marijuana-on-neuropathic-pain-106865https://curecurrent.com/trials/a-study-of-everolimus-in-the-treatment-of-neurocognitive-problems-in-tuberous-sclerosis-106866https://curecurrent.com/trials/trial-of-rad001-and-neurocognition-in-tuberous-sclerosis-complex-tsc-106867https://curecurrent.com/trials/caprylic-triglyceride-for-treatment-of-cognitive-impairments-in-multiple-sclerosis-106868https://curecurrent.com/trials/single-center-open-label-study-of-preparation-h-on-erythema-in-relapsing-ms-patients-treated-with-plegridy-106869https://curecurrent.com/trials/observational-study-of-the-prevalence-of-ccsvi-in-multiple-sclerosis-and-in-other-neurodegenerative-diseases-106870https://curecurrent.com/trials/understanding-evaluation-of-patient-information-sheets-by-user-testing-method-106871https://curecurrent.com/trials/effect-of-vitamin-d-replacement-on-immune-function-and-cognition-in-ms-patients-106872https://curecurrent.com/trials/efficacy-of-lower-limb-exercises-on-overactive-bladder-symptoms-in-patients-with-multiple-sclerosis-106873https://curecurrent.com/trials/ms-symptom-management-study-106874https://curecurrent.com/trials/a-multicentre-study-of-the-efficacy-and-safety-of-supplementary-treatment-with-cholecalciferol-in-patients-with-relapsin-106875https://curecurrent.com/trials/multiple-sclerosis-collaborative-approach-to-rehabilitation-effectiveness-study-106876https://curecurrent.com/trials/pediatric-onset-multiple-sclerosis-in-egyptians-106877https://curecurrent.com/trials/effectiveness-of-acceptance-and-commitment-therapy-self-help-for-carers-of-people-with-multiple-sclerosis-106878https://curecurrent.com/trials/task-oriented-circuit-training-combined-with-cerebellar-tdcs-in-multiple-sclerosis-subjects-106879https://curecurrent.com/trials/effect-of-video-game-based-physical-activity-training-in-persons-with-multiple-sclerosis-106880https://curecurrent.com/trials/optical-coherence-tomography-oct-trial-in-multiple-sclerosis-106881https://curecurrent.com/trials/a-pilot-study-of-intermittent-calorie-restriction-in-multiple-sclerosis-106882https://curecurrent.com/trials/integrative-group-based-cognitive-rehabilitation-efficacy-in-multiple-sclerosis-106883https://curecurrent.com/trials/betaeval-global-the-new-betaconnect-auto-injector-adherence-and-evaluation-of-multiple-sclerosis-patients-treated-with-b-106884https://curecurrent.com/trials/cognitive-evolution-in-tysabri-treated-multiple-sclerosis-patients-a-three-year-extension-106885https://curecurrent.com/trials/stress-urinary-incontinence-in-women-with-multiple-sclerosis-106886https://curecurrent.com/trials/participants-preferences-to-disease-modifying-agents-in-relapsing-remitting-multiple-sclerosis-condition-106887https://curecurrent.com/trials/the-effect-of-high-intensity-interval-training-on-cardiovascular-fitness-in-people-with-progressive-multiple-sclerosis-106888https://curecurrent.com/trials/tysabri-effects-on-cognition-and-neurodegeneration-in-multiple-sclerosis-106889https://curecurrent.com/trials/study-of-the-effect-of-bg00012-on-mri-lesions-and-pharmacokinetics-in-pediatric-subjects-with-rrms-106890https://curecurrent.com/trials/bay86-5046-betaseron-non-interventional-studies-106891https://curecurrent.com/trials/endpoint-calibration-for-a-phase-2-study-of-lisinopril-in-multiple-sclerosis-106892https://curecurrent.com/trials/respiratory-monitoring-of-intrathecal-baclofen-a-feasibility-study-106893https://curecurrent.com/trials/comparison-of-oral-molecules-preventing-relapses-in-multiple-sclerosis-106894https://curecurrent.com/trials/evaluation-of-the-safety-tolerability-and-efficacy-of-orally-administered-ptl201-in-ms-patients-with-spasticity-related-106895https://curecurrent.com/trials/efficacy-and-safety-of-fingolimod-in-patients-with-relapsing-remitting-multiple-sclerosis-with-optional-extension-phase-106896https://curecurrent.com/trials/nogo-a-in-multiple-sclerosis-ftih-106897https://curecurrent.com/trials/high-dose-immunosuppression-and-autologous-transplantation-for-multiple-sclerosis-halt-ms-study-106898https://curecurrent.com/trials/efficacy-and-safety-of-fty720-in-patients-with-relapsing-multiple-sclerosis-106899https://curecurrent.com/trials/teriflunomide-s-therapeutic-mechanisms-of-action-in-patients-with-relapsing-remitting-multiple-sclerosis-106900https://curecurrent.com/trials/a-clinical-study-of-the-efficacy-of-natalizumab-on-reducing-disability-progression-in-participants-with-secondary-progre-106901https://curecurrent.com/trials/expanded-access-program-for-ocrelizumab-in-participants-with-primary-progressive-multiple-sclerosis-106902https://curecurrent.com/trials/evaluation-of-the-response-to-acthar-gel-therapy-in-patients-who-failed-intravenous-methylprednisolone-ivmp-for-ms-relap-106903https://curecurrent.com/trials/long-term-study-of-avonex-therapy-following-a-first-attack-of-multiple-sclerosis-106904https://curecurrent.com/trials/intensive-multimodal-training-for-persons-with-ms-106905https://curecurrent.com/trials/study-to-assess-the-safety-and-effects-of-autologous-adipose-derived-stromal-cells-delivered-into-patients-with-multiple-106906https://curecurrent.com/trials/a-phase-1-trial-of-intrathecal-rituximab-for-progressive-multiple-sclerosis-patients-106907https://curecurrent.com/trials/characterizing-upper-extremity-function-in-individuals-with-multiple-sclerosis-106908https://curecurrent.com/trials/pilot-trial-of-backwards-walking-in-persons-with-multiple-sclerosis-106909https://curecurrent.com/trials/quantitation-of-mcardle-s-sign-and-evaluation-of-specificity-for-multiple-sclerosis-106910https://curecurrent.com/trials/gut-microbiota-and-multiple-sclerosis-106911https://curecurrent.com/trials/a-phase-4-study-to-assess-the-impact-of-patient-support-program-on-health-related-quality-of-life-and-adherence-in-subje-106912https://curecurrent.com/trials/effect-of-active-passive-trainer-cycling-on-multiple-sclerosis-106913https://curecurrent.com/trials/a-trial-for-evaluating-both-safety-and-preliminary-efficacy-of-a-single-infusion-of-stimulated-autologous-cd4-t-cells-in-106914https://curecurrent.com/trials/physical-activity-in-multiple-sclerosis-ms-a-novel-approach-to-study-outcomes-106915https://curecurrent.com/trials/prognosis-value-of-the-neuronal-damage-in-early-multiple-sclerosis-106916https://curecurrent.com/trials/feasibility-study-of-human-umbilical-cord-tissue-derived-mesenchymal-stem-cells-in-patients-with-multiple-sclerosis-106917https://curecurrent.com/trials/safety-and-efficacy-of-ads-5102-in-patients-with-multiple-sclerosis-and-walking-impairment-106918https://curecurrent.com/trials/a-telemedicine-mindfulness-based-intervention-for-people-with-multiple-sclerosis-and-their-caregivers-106919https://curecurrent.com/trials/cc100-phase-1-multiple-dose-safety-and-tolerability-in-subjects-with-als-106920https://curecurrent.com/trials/a-phase-1-study-of-arn-6039-106921https://curecurrent.com/trials/firategrast-sb683699-surface-area-study-in-multiple-sclerosis-patients-106922https://curecurrent.com/trials/quantitative-imaging-and-proton-spectroscopy-in-multiple-sclerosis-106923https://curecurrent.com/trials/evaluation-of-coagulation-in-multiple-sclerosis-106924https://curecurrent.com/trials/disability-perceived-social-support-and-quality-of-life-in-multiple-sclerosis-106925https://curecurrent.com/trials/gsk239512-ddi-study-106926https://curecurrent.com/trials/the-murdock-study-community-registry-and-biorepository-multiple-sclerosis-cohort-106927https://curecurrent.com/trials/study-of-utilization-patterns-of-dimethyl-fumarate-in-germany-106928https://curecurrent.com/trials/safety-and-efficacy-study-of-mis416-to-treat-secondary-progressive-multiple-sclerosis-106929https://curecurrent.com/trials/sabril-for-complex-partial-seizures-in-adult-tolerability-study-ts-patients-106930https://curecurrent.com/trials/study-evaluating-betaferons-safety-and-tolerability-in-pediatric-patients-with-multiple-sclerosis-106931https://curecurrent.com/trials/comparison-of-craniosacral-therapy-vs-pelvic-floor-physical-therapy-106932https://curecurrent.com/trials/a-study-to-assess-the-relative-bioavailability-of-different-formulations-of-gsk2018682-a-sphingosine-1-phosphate-recepto-106933https://curecurrent.com/trials/healthy-volunteer-study-using-3-different-formulations-of-firategrast-106934https://curecurrent.com/trials/assessment-of-repeat-ascending-doses-of-gsk2018682-in-healthy-volunteers-106935https://curecurrent.com/trials/pupillometry-dynamic-measures-in-patients-without-ocular-or-neurological-disease-106936https://curecurrent.com/trials/magnetic-resonance-imaging-to-detect-brain-damage-in-patients-with-multiple-sclerosis-106937https://curecurrent.com/trials/stylistic-memory-enhancement-106938https://curecurrent.com/trials/immunological-mechanisms-of-hematopoietic-stem-cell-transplantation-in-multiple-sclerosis-106939https://curecurrent.com/trials/assessment-of-patients-with-multiple-sclerosis-ms-106940https://curecurrent.com/trials/zenapax-daclizumab-to-treat-relapsing-remitting-multiple-sclerosis-106941https://curecurrent.com/trials/atx-ms-1467-in-multiple-sclerosis-106942https://curecurrent.com/trials/treating-new-learning-and-memory-deficits-in-progressive-multiple-sclerosis-ms-106943https://curecurrent.com/trials/magnetic-resonance-imaging-to-detect-brain-damage-in-patients-with-multiple-sclerosis-106944https://curecurrent.com/trials/magnetic-resonance-imaging-to-detect-brain-damage-in-patients-with-multiple-sclerosis-106945https://curecurrent.com/trials/exercise-in-multiple-sclerosis-effects-on-cognitive-function-and-brain-connectivity-106946https://curecurrent.com/trials/multiple-sclerosis-associated-cardiometabolic-risks-and-impact-of-exercise-therapy-106947https://curecurrent.com/trials/the-effect-of-alemtuzumab-on-the-blood-brain-barrier-and-the-brain-s-metabolism-in-multiple-sclerosis-patients-106948https://curecurrent.com/trials/healthy-volunteer-pilot-study-using-3-types-of-modified-release-formulations-of-firategrast-to-investigate-how-quickly-a-106949https://curecurrent.com/trials/cognitive-impairment-in-pediatric-onset-multiple-sclerosis-106950https://curecurrent.com/trials/virtual-reality-and-manual-dexterity-in-in-patients-with-multiple-sclerosis-106951https://curecurrent.com/trials/this-was-an-open-label-single-arm-extension-study-cfty720d2306e1-to-a-double-blind-randomized-multicenter-placebo-contro-106952https://curecurrent.com/trials/impact-of-natalizumab-versus-fingolimod-in-relapsing-remitting-multiple-sclerosis-rrms-participants-106953https://curecurrent.com/trials/gsk2018682-ftih-in-healthy-volunteers-106954https://curecurrent.com/trials/fish-oil-for-the-treatment-of-depression-in-patients-with-multiple-sclerosis-106955https://curecurrent.com/trials/a-first-time-in-human-study-exploring-safety-tolerability-pharmacokinetics-pk-and-pharmacodynamics-pd-of-gsk2618960-in-h-106956https://curecurrent.com/trials/effect-of-guided-imagery-on-well-being-in-patients-with-multiple-sclerosis-106957https://curecurrent.com/trials/testing-a-resilience-intervention-for-individuals-aging-with-multiple-sclerosis-ms-106958https://curecurrent.com/trials/natalizumab-as-an-efficacy-switch-in-participants-with-relapsing-multiple-sclerosis-after-failure-on-other-therapies-106959https://curecurrent.com/trials/vaccination-response-in-tecfidera-treated-versus-interferon-treated-participants-with-relapsing-forms-of-multiple-sclero-106960https://curecurrent.com/trials/lipoic-acid-and-omega-3-fatty-acids-for-cognitive-impairment-in-multiple-sclerosis-106961https://curecurrent.com/trials/web-based-physiotherapy-for-people-with-multiple-sclerosis-106962https://curecurrent.com/trials/armergometry-to-improve-mobility-in-ms-106963https://curecurrent.com/trials/measuring-signatures-in-the-fluid-surrounding-the-spinal-cord-in-patients-who-have-problems-with-intrathecal-drug-delive-106964https://curecurrent.com/trials/raltegravir-isentress-pilot-study-in-relapsing-multiple-sclerosis-106965https://curecurrent.com/trials/an-observational-pilot-study-of-lumosity-computerized-cognitive-training-in-subjects-with-multiple-sclerosis-106966https://curecurrent.com/trials/real-life-outcomes-of-multiple-sclerosis-treatment-with-rebif-106967https://curecurrent.com/trials/abdominal-massage-for-bowel-dysfunction-106968https://curecurrent.com/trials/study-to-evaluate-intravenous-and-oral-steroids-for-multiple-sclerosis-attacks-106969https://curecurrent.com/trials/study-to-evaluate-whether-a-medication-event-monitoring-system-mems-can-improve-adherence-to-tecfidera-treatment-in-mult-106970https://curecurrent.com/trials/analyze-the-myelin-trap-as-diagnostic-tool-in-multiple-sclerosis-106971https://curecurrent.com/trials/an-extension-protocol-for-multiple-sclerosis-patients-who-participated-in-genzyme-sponsored-studies-of-alemtuzumab-106972https://curecurrent.com/trials/tecfidera-slow-titration-study-106973https://curecurrent.com/trials/motivational-interviewing-to-increase-physical-activity-to-treat-depression-in-people-aging-with-ms-or-sci-106974https://curecurrent.com/trials/reduced-intensity-immunoablation-and-autologous-hematopoietic-stem-cell-transplantation-ahsct-for-multiple-sclerosis-106975https://curecurrent.com/trials/topical-rapamycin-and-calcitriol-for-angiofibroma-of-tuberous-sclerosis-106976https://curecurrent.com/trials/tuberous-sclerosis-complex-natural-history-study-renal-manifestations-106977https://curecurrent.com/trials/dose-related-effects-of-vitamin-d3-on-immune-responses-in-patients-with-clinically-isolated-syndrome-106978https://curecurrent.com/trials/evidence-based-patient-information-and-smartphone-accelerometry-to-enhance-physical-activity-in-ms-106979https://curecurrent.com/trials/study-to-assess-the-efficacy-safety-tolerability-and-pharmacokinetics-of-biib033-in-participants-with-relapsing-forms-of-106980https://curecurrent.com/trials/the-effect-of-melatonin-on-gene-expression-and-activity-of-the-sirt1-and-its-target-genes-catalase-and-mnsod-in-multiple-106981https://curecurrent.com/trials/safety-and-efficacy-study-of-autologus-bone-marrow-mesenchymal-stem-cells-in-multiple-sclerosis-106982https://curecurrent.com/trials/atorvastatin-lipitor-therapy-in-patients-with-clinically-isolated-syndrome-cis-at-risk-for-multiple-sclerosis-106983https://curecurrent.com/trials/study-assessing-cognition-in-relapsing-remitting-multiple-sclerosis-rrms-patients-treated-with-bg00012-106984https://curecurrent.com/trials/an-online-self-guided-meditation-course-for-individuals-with-multiple-sclerosis-106985https://curecurrent.com/trials/the-role-of-exercise-in-modifying-outcomes-for-people-with-multiple-sclerosis-106986https://curecurrent.com/trials/bg00012-and-delay-of-disability-progression-in-secondary-progressive-multiple-sclerosis-106987https://curecurrent.com/trials/improving-memory-in-patients-with-multiple-sclerosis-106988https://curecurrent.com/trials/safety-and-efficacy-of-fingolimod-in-ms-patients-in-china-106989https://curecurrent.com/trials/engyne-exploring-gilenya-in-patients-with-neutralizing-antibodies-against-interferon-106990https://curecurrent.com/trials/efficacy-of-5-weeks-of-treatment-with-bgg492-in-patients-with-spasticity-due-to-multiple-sclerosis-106991https://curecurrent.com/trials/pulse-acth-vs-mp-for-ms-106992https://curecurrent.com/trials/gastrointestinal-tolerability-study-of-dimethyl-fumarate-in-participants-with-relapsing-remitting-multiple-sclerosis-in-106993https://curecurrent.com/trials/comparison-of-alemtuzumab-and-rebif-efficacy-in-multiple-sclerosis-study-two-106994https://curecurrent.com/trials/safety-and-efficacy-of-avp-923-in-pba-patients-with-als-or-ms-106995https://curecurrent.com/trials/ofatumumab-dose-finding-in-relapsing-remitting-multiple-sclerosis-rrms-patients-106996https://curecurrent.com/trials/improved-detection-of-multiple-sclerosis-plaques-in-inversion-recovery-by-optimization-of-sequence-parameters-106997https://curecurrent.com/trials/examining-the-effects-of-video-game-exercise-on-mobility-and-brain-plasticity-in-individuals-with-multiple-sclerosis-106998https://curecurrent.com/trials/at-risk-for-ms-clinical-conversion-of-female-monozygotic-twins-discordant-for-cis-ms-106999https://curecurrent.com/trials/efficacy-study-of-imaginative-distention-a-self-managed-tool-to-cope-with-fatigue-insomnia-and-stress-in-pw-insomnia-and-107000https://curecurrent.com/trials/the-effect-of-natalizumab-tysabri-on-sexual-dysfunction-in-multiple-sclerosis-107001https://curecurrent.com/trials/effects-of-the-cross-training-in-patients-with-multiple-sclerosis-107002https://curecurrent.com/trials/developing-and-testing-a-comprehensive-ms-spasticity-management-program-107003https://curecurrent.com/trials/gadobutrol-versus-gadopentetate-dimeglumine-or-gadobenate-dimeglumine-before-dce-mri-in-diagnosing-patients-with-multipl-107004https://curecurrent.com/trials/effect-of-md1003-in-chronic-visual-loss-related-to-optic-neuritis-in-multiple-sclerosis-107005